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MOBILE PHONE TEXT MESSAGING FOR IMPROVING  
THE UPTAKE OF VACCINATIONS:  




The	  research	  undertaken	  for	  this	  MPH	  dissertation	  examines	  the	  effectiveness	  of	  SMS	  as	  an	  
intervention	  to	  promote	  vaccination.	  
	  
Part	   A	   is	   the	   research	   protocol,	   which	   outlines	   the	   background	   and	   the	   process	   of	   this	  
research.	   	   This	   study	   utilizes	   systematic	   review	   methods	   based	   on	   those	   of	   the	   Cochrane	  
Collaboration	   to	   synthesize	   the	   best	   current	   evidence	   from	   articles	   archived	   in	   various	  
bibliographic	  databases	  and	  clinical	  trial	  registers.	  	  	  
	  
Part	   B	   presents	   the	  entire	   research	  project	   in	  a	   format	   suitable	   for	   journal	   submission.	  The	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Background:  Low	  vaccine	  coverage	  is	  a	  major	  public	  health	  concern,	  the	  consequences	  of	  
which	   contribute	   to	   around	   1.5	   million	   child	   deaths	   from	   vaccine-­‐preventable	   diseases.	  	  
Thus,	  innovative	  strategies	  to	  rapidly	  increase	  coverage	  and	  recall	  rates	  for	  vaccinations	  are	  
urgently	  required.	  	  Mobile	  phone	  text	  messaging	  (or	  short	  messaging	  service,	  SMS)	  has	  the	  
potential	   to	   help	   increase	   vaccination	   coverage	   and	   therefore	   we	   propose	   to	   conduct	   a	  




This	   article	   describes	   the	   protocol	   for	   a	   systematic	   review	   of	   the	   effectiveness	   of	   SMS	   in	  
improving	  the	  uptake	  of	  vaccination.	  	  Primary	  and	  secondary	  outcomes	  of	  interest	  are	  pre-­‐
specified.	   	  We	  will	   preferably	   include	   randomized	   controlled	   trials	   (RCTs).	   However,	   non-­‐
randomized	  studies	  (NRS)	  will	  be	  considered	  if	  there	  is	  an	  inadequate	  number	  of	  RCTs.	  We	  
will	   search	   several	   bibliographic	   databases	   (for	   example	   PubMed,	   EMBASE,	   CINAHL,	  
CENTRAL,	  Science	  Citation	  Index,	  Africa-­‐Wide	  Information,	  and	  WHOLIS	  electronic	  databases	  
and	  search	  sources	  for	  grey	  literature.	  	  Following	  data	  extraction	  and	  assessment	  of	  risk	  of	  
bias,	   we	   will	   meta-­‐analyze	   studies	   and	   conduct	   sub-­‐group	   analyses,	   according	   to	  
intervention	   subtypes.	  We	  will	   assess	   clinical	   heterogeneity	   and	   statistical	   heterogeneity.	  
For	  outcomes	  without	  quantitative	  data,	  a	  descriptive	  analysis	  will	  be	  used.	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Discussion:	  	  
Our	  results	  can	  be	  used	  by	  researchers	  and	  policy-­‐makers	  to	  help	  inform	  them	  of	  the	  
efficacy	  of	  mobile	  phone	  text	  messaging	  interventions	  to	  promote	  increased	  vaccination	  
coverage.	  
Keywords:	  	  Vaccine	  coverage,	  vaccination,	  Mobile	  text	  messaging,	  short	  messaging	  service,	  
SMS	  	  




Vaccinations,	  when	  given	  at	   the	  most	  sensitive	  developmental	  years	  of	  childhood,	  help	   to	  
promote	   comprehensive	   and	   capable	   immunity,	   enabling	   children	   to	   fight	   off	   certain	  
diseases	   (Garde,	   2010,	   Multiple	   Authors.,	   2009).	   In	   addition,	   vaccinations	   are	   widely	  
regarded	  as	  one	  of	  the	  most	  cost-­‐effective	  public	  health	   interventions	  that	  help	  to	  reduce	  
global	  child	  morbidity	  and	  mortality	  (Machingaidze	  et	  al.,	  2013,	  Bloom,	  2011).	  Low	  coverage	  
of	   vaccinations	   is	   a	  major	  public	  health	   concern.	   In	  Africa	   alone,	  more	   than	   seven	  million	  
children	   did	   not	   receive	   the	   full	   spectrum	   of	   vaccinations	   recommended	   before	   reaching	  
one	  year	  of	  age	  in	  2009	  (Stockwell	  et	  al.,	  2012).	  It	  is	  also	  estimated	  that	  1.5	  million	  children	  
died	   globally	   from	   vaccine-­‐preventable	   diseases	  where	  World	  Health	  Organization	   (WHO)	  
pre-­‐qualified	   vaccines	   were	   available	   (World	   Health	   Organisation	   and	   UNICEF:	   	   Global	  
Immunization	  Data.).	  
	  
The	  Global	  Vaccine	  Action	  plan	   (GVAP)	   is	   the	  most	   recently	   launched	  global	   effort	  by	   the	  
WHO	   to	   help	   increase	   vaccination	   coverage.	   The	   GVAP	   has	   set	   a	   target	   that	   by	   2020	  
vaccination	  coverage	  for	  populations	  should	  reach	  90%	  national	  vaccination	  coverage	  and	  at	  
least	   80%	   at	   district	   levels	   utilizing	   national	   vaccination	   programmes	   (WHO	   Global	  
Vaccination	   Action	   Plan).	   It	   is	   guided	   by	   six	   principles:	   country	   ownership,	   shared	  
responsibility	  and	  partnership,	  equity,	  integration,	  sustainability,	  and	  innovation	  (Decade	  of	  
Vaccines	  (DoV)	  Collaboration:	  Draft	  global	  vaccine	  action	  plan.)	  	  
	  
A	  variety	  of	   factors	   impact	  achieving	   low	  coverage	  rates;	  challenges	  such	  as	   immunisation	  
awareness,	  demand	  for	  immunisation,	  level	  of	  trust	  in	  the	  health	  system,	  adequate	  human	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resources,	   access,	   timeliness	   of	   vaccinations,	   service	   delivery,	   poor	   infrastructure	   and	  
vaccination	   monitoring	   (Machingaidze	   et	   al.,	   2013).	   	   Vaccination	   coverage	   seems	   to	   be	  
lower	   in	   low-­‐income	  households,	  where	   limited	  access	  to	  health	  education,	  contributes	  to	  
poor	  health-­‐seeking	  behaviour	  along	  with	  an	  inability	  to	  improve	  general	  wellbeing	  (Garde,	  
2010,	   Multiple	   Authors.,	   2009,	   Kaewkungwal	   et	   al.,	   2010).	   Uneducated	   adults	   as	   well	   as	  
parents	   of	   children	   who	   require	   vaccinations	   may	   be	   less	   likely	   to	   understand	   the	  
importance	   of	   vaccinating	   to	   prevent	   potentially	   harmful	   diseases.	   	   In	   light	   of	   these	  
obstacles	  to	  vaccination	  coverage,	  the	  strategy	  to	  improve	  vaccination	  coverage	  needs	  to	  be	  
innovative	  as	  alluded	   to	   in	   the	  GVAP,	  well	   thought	  out	  and	  able	   to	  penetrate	   low	   income	  
households	  effectively.	  
	  
Globally,	  mobile	  phone	  use	  is	  rapidly	  increasing,	  with	  an	  estimated	  six	  billion	  mobile	  phone	  
users	  worldwide	  at	   the	  end	  of	  2011	   (Nglazi	  et	  al.,	  2013).	   	   In	  particular,	  mobile	  phone	  text	  
messaging	  has	  gained	  popularity	  among	  people	  living	  in	  low-­‐	  and	  middle-­‐income	  countries	  
and	   may	   be	   the	   key	   to	   penetrating	   hard	   to	   reach	   areas	   in	   the	   developing	   world.	   Text	  
messaging	   has	   proven	   to	   be	   a	   cost	   effective	   method	   of	   relaying	   health	   information	   and	  
reminders	  than	  the	  more	  traditional	  methods	  such	  as	  face	  to	  face,	  phone	  calls,	  pamphlets,	  
mail	   and	   email	   (Stockwell	   et	   al.,	   2012).	   As	   immunisation	   usually	   requires	   multiple	  
consecutive	  monthly	   visits	   after	   the	   first	   vaccine	  dose	   in	  order	   to	   complete	   the	   schedule,	  
short	  messaging	   service	   (SMS)	   can	   be	   used	   as	   reminder	   for	   an	   upcoming	   visit	   and	   recall	  
when	  a	  visit	  has	  been	  missed	  (Garde,	  2010).	  In	  addition,	  an	  SMS	  intervention,	  also	  known	  as	  
mobile	  phone	  text	  messaging,	  can	  be	  delivered	  alone	  or	  bundled	  with	  other	   interventions	  
(Mohammed	  et	  al.,	  2012).	  	  Diseases	  that	  have	  used	  mobile	  technology	  successfully	  include	  
HIV	  where	  a	  90%	  adherence	  was	  observed	  among	  text	  message	  recipients	  compared	  with	  a	  
ROBYN	  KALAN,	  BLGROB001:	  	  DISSERTATION	  PROTOCOL	   07	  February	  2014	  
Page	  7	  
40%	  adherence	  in	  the	  control	  group	  (Pop-­‐Eleches	  et	  al.,	  2011).	  	  Similarly,	  SMS	  interventions	  
have	   been	   shown	   to	   improve	   self-­‐management	   interventions	   for	   chronic	   conditions	  
including	  behaviour	  modification	  smoking	  quit	  rates	  (Jones	  et	  al.,	  2014)	  	  
	  
We	  therefore	  propose	  to	  conduct	  a	  systematic	  review	  of	  the	  current	  best	  evidence	  for	  the	  
use	  of	  mobile	  phone	  text	  messaging	  to	  improve	  vaccination	  coverage.	  
Methods	  
The	   review	   protocol	   has	   not	   been	   registered	   in	   any	   prospective	   registers	   of	   systematic	  
reviews.	  
	  
Criteria	  for	  considering	  studies	  for	  this	  review	  
	  
Type	  of	  studies	  
We	  will	  include	  randomized	  controlled	  trials	  (RCTs),	  interrupted	  time	  series	  and	  controlled	  
before	  and	  after	  studies	  (CBA).	  	  	  
	  
Types	  of	  participants	  
Participants	   will	   be	   adults,	   children	   or	   their	   caregivers	   of	   those	   receiving	   vaccinations,	   in	  
community-­‐based	  settings.	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Types	  of	  interventions	  
We	  will	   include	   interventions	   in	  which	  mobile	   phone	   text	  messages	   are	   used	   to	   promote	  
uptake	   of	   vaccinations.	   The	   text	  messaging	   needs	   to	   be	   delivered	   to	   a	   person	   needing	   a	  
vaccination,	  or	  in	  the	  case	  of	  an	  infant	  or	  child,	  to	  a	  caregiver.	  Eligible	  studies	  will	  be	  those	  
that	   compare	  SMS	   to	  no	   intervention,	  or	   to	  other	   interventions	   for	   increasing	  vaccination	  
coverage.	  If	  we	  find	  less	  than	  ten	  studies	  that	  include	  only	  SMS	  as	  the	  intervention,	  we	  will	  
include	   studies	   in	   which	   (1)	   mobile	   phone	   voice	   speaking	   or	   voice	   messaging	   are	  
interventions	  including	  interactive	  voice	  response	  known	  as	  IVR;	  (2)	  studies	  in	  which	  the	  use	  
of	   a	   beeper	   or	   pager	   is	   the	   intervention;	   (3)	   studies	   in	   which	   the	   use	   of	   multimedia	  
messaging	  service	   is	  the	   intervention;	  (4)	  studies	   in	  which	  text	  messages	  are	  bundled	  with	  
other	   interventions.	   In	   such	   circumstances,	   we	   will	   stratify	   the	   analysis	   by	   type	   of	  
intervention.	  
	  
Types	  of	  outcome	  measures	  	  	  
Results	  must	  include	  quantitative	  data	  for	  outcomes	  measured.	  
Primary	  outcomes:	  	  
The	  primary	  outcome	  is	  vaccination	  coverage,	  irrespective	  of	  disease.	  	  
	  
Secondary	  outcomes:	  	  	  
Secondary	   outcomes	   are	   the	   recall	   rate	   in	   persons	   who	   had	   previously	   missed	   their	  
vaccinations.	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Search	  methods	  for	  identification	  of	  studies	  
A	   comprehensive	   and	   exhaustive	   search	   will	   be	   performed	   by	   RK	   with	   the	   help	   of	   the	  
University	  of	  Cape	  Town	  librarian,	  to	  identify	  all	  relevant	  studies	  available	  by	  30	  June	  2013,	  
regardless	   of	   language	   or	   publication	   status.	   We	   will	   search	   both	   peer-­‐reviewed	   journal	  
articles	  and	  grey	  literature	  (unpublished,	  internal	  or	  non-­‐reviewed	  papers	  and	  reports).	  
	  
Database	  
We	   will	   search	   the	   following	   electronic	   databases:	   PubMed;	   EMBASE;	   Cochrane	   Central	  
Register	  of	  Controlled	  Trials	  (CENTRAL);	  ISI	  Web	  of	  Science	  (Science	  Citation	  Index);	  Africa-­‐
Wide	  Information,	  Cumulative	  Index	  of	  Nursing	  and	  Allied	  Health	  (CINAHL),	  and	  WHO	  library	  
databases	   (WHOLIS).	   We	   will	   use	   both	   text	   words	   and	   medical	   subject	   heading	   (MeSH)	  
terms;	   for	   example	   vaccination*,	   immunization*,	   immunisation*,	   "Immunization"(MeSH),	  	  
"Vaccination"(MeSH),	   	   "Immunization,	   Secondary"(MeSH)	   OR	   "Immunization	  
Programs"(MeSH),	   	   "Immunization	   Schedule"(MeSH),	   "Mass	   Vaccination"(MeSH),	   mobile	  
phone,	  text	  messaging,	  text*,	  SMS,	  reminder*,	  recall,	  telemedicine,	  mHealth,	  and	  eHealth.	  
These	   terms	   will	   be	   used	   in	   varying	   combinations.	   The	   literature	   search	   strategy	   will	   be	  
adapted	  to	  suit	  each	  database.	  Table	  1	  shows	  the	  main	  search	  strategy	  we	  will	  use.	  
	  
Conference	  proceedings	  
We	   will	   search	   the	   following	   conference	   proceedings	   for	   relevant	   abstracts:.	   Vaccine	   and	  
International	   Society	   for	   Vaccines	   Congress,	   International	   African	   Vaccinology	   Conference,	  
Annual	   Vaccines	   Congress,	   Annual	   Conference	   on	   Vaccine	   Research,	   World	   Congress	   on	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Pediatric	   Infectious	   Diseases,	   International	   Pediatric	   Association	   Conference,	   National	  
Immunization	  Conference,	  and	  the	  Annual	  Infectious	  Diseases	  in	  Children	  Symposium.	  
	  
Searching	  other	  sources	  
For	  ongoing	  studies,	  we	  will	  search	  the	  WHO	  International	  Clinical	  trials	  Registry	  Platform,	  
Clinicaltrials.gov,	   Pan	   African	   Clinical	   Trials	   Registry	   (PACTR),	   and	   contact	   individual	  
researchers	  working	  in	  the	  field	  as	  well	  as	  the	  following	  organizations:	  WHO,	  Global	  Alliance	  
for	  Vaccines	  and	   Immunisation,	  Centers	   for	  Disease	  Control	   and	  Prevention,	   and	  mHealth	  
Alliance.	   We	   will	   also	   search	   the	   website	   of	   mHealth	   Alliance	   and	   mHealth	   in	   the	   Low	  
Resource	  Settings	  resources	  database	  [20]	  for	  eligible	  studies.	  
	  
Reference	  lists	  
We	   will	   obtain	   reference	   lists	   of	   relevant	   studies	   identified	   and	   the	   full-­‐text	   articles	  
reviewed	  for	  inclusion	  in	  the	  review	  will	  be	  checked	  for	  additional	  information.	  
	  
Data	  collection	  and	  analysis	  
The	  methods	  for	  data	  collection	  and	  analysis	  will	  be	  based	  on	  the	  Cochrane	  Handbook	  of	  
Systematic	  Reviews	  for	  Interventions	  (Higgins	  et	  al.,	  2009).	  
	  
Selection	  of	  studies	  
We	  will	  construct	  a	  screening	  guide	  to	  ensure	  that	  the	  inclusion	  criteria	  are	  adhered	  to	  and	  
consistently	   applied	   by	   all	   review	   authors.	   Two	   review	   authors	   (RK	   and	   ME),	   working	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independently,	   will	   screen	   the	   titles	   and	   abstracts	   of	   all	   studies	   identified	   through	   the	  
literature	   searches	   for	  eligibility.	  RK	  will	  obtain	   the	   full	   text	  of	   studies	  deemed	  potentially	  
eligible.	  The	  two	  authors	  (RK	  and	  ME)	  will	  independently	  assess	  the	  full	  text	  of	  each	  article	  
for	   eligibility,	   and	   compare	   their	   results	   and	   resolve	   discrepancies	   by	   discussion	   and	  
consensus,	  consulting	  a	   third	  author	   (CW)	  to	  resolve	  any	  persistent	  disagreements.	  For	  all	  
studies	  excluded	  by	  the	  assessors	  we	  will	  describe	  the	  reasons	  for	  exclusion.	  
	  
Data	  extraction	  and	  management	  
References	  will	  be	  managed	  using	  Thomson	  ISI	  Research-­‐Soft	  Endnote	  9.0	  (Thomson).	  Two	  
authors	  will	   independently	  extract	  descriptive	  and	  outcome	  data	   for	  each	   included	  article	  
using	   a	   standardized	   data	   collection	   form,	   resolving	   any	   discrepancies	   by	   discussion	   and	  
consensus;	  failing	  which,	  a	  third	  author	  (CW)	  will	  arbitrate.	  	  RK	  will	  enter	  the	  final	  data	  into	  
the	   Cochrane	   Collaboration	   Review	   Manager	   Version	   5.1	   statistical	   software	  
(http://ims.cochrane.org/RevMan).	   	   CW	   will	   crosscheck	   the	   data	   entered	   to	   ensure	   that	  
there	  are	  no	  data	  entry	  errors.	  
	  
Assessment	  of	  risk	  of	  bias	  in	  included	  studies	  
Two	   authors	   will	   independently	   assess	   the	   risk	   of	   bias	   in	   the	   included	   studies.	   Separate	  
criteria	  will	  be	  used	  to	  assess	  RCTs	  and	  non-­‐randomized	  studies.	  The	  criteria	  used	  to	  assess	  
the	   risk	   of	   bias	   of	   in	   RCTs	   will	   be	   random	   sequence	   generation;	   allocation	   concealment;	  
blinding	   of	   participants,	   study	   personnel;	   blinding	   of	   outcome	   assessors;	   incomplete	  
outcome	  data;	  selective	  outcome	  reporting;	  other	  sources	  of	  bias,	  and	  overall	  risk	  of	  bias,	  in	  
accordance	  with	  the	  methods	  used	  by	  the	  Cochrane	  Collaboration	  (Higgins	  et	  al.)	  as	  well	  as	  
the	   Cochrane	  Consumers	   and	  Communication	  Review	  Group	   (Ryan	  R,	   2011).	   	   The	   criteria	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used	  for	  risk	  of	  bias	  assessment	  for	  non-­‐randomized	  studies	  will	  include	  selection	  bias	  (with	  
regard	   to	   comparability	   of	   groups,	   confounding	   and	   adjustment);	   performance	   bias	   (in	  
terms	   of	   the	   fidelity	   of	   the	   interventions,	   and	   quality	   of	   the	   information	   regarding	   who	  
received	  which	  interventions,	  including	  blinding	  of	  study	  subjects	  and	  healthcare	  providers);	  
detection	  bias	  (regarding	  unbiased	  and	  correct	  assessment	  of	  outcomes,	  including	  blinding	  
of	   assessors);	   attrition	   bias	   (with	   regard	   to	   completeness	   of	   sample,	   follow-­‐up	   and	   data);	  
and	   reporting	   bias	   (with	   regard	   to	   publication	   biases	   and	   selective	   reporting	   of	   results)	  
(Higgins	  et	  al.,	  2009).	  Studies	  will	  be	  scored	  as	  having	  low,	  high	  or	  unclear	  risk	  of	  bias.	  The	  
two	  authors	  will	  resolve	  disagreements	   in	  the	  assessment	  of	  risk	  of	  bias	  by	  discussion	  and	  
consensus,	  consulting	  a	  third	  author	  to	  resolve	  any	  persistent	  disagreements.	  
	  
Measures	  of	  treatment	  effect	  
Data	  analysis	  will	  be	  conducted	  using	  the	  Cochrane	  Collaboration	  Review	  Manager	  Version	  
5.1	  statistical	  software	  (http://ims.cochrane.org/RevMan).	  The	  outcomes	  of	  interest	  will	  be	  
either	  dichotomous	  or	  continuous.	  We	  will	  calculate	  risk	  ratios	  and	  their	  corresponding	  95%	  
confidence	  intervals	  or	  p-­‐values	  for	  dichotomous	  outcomes,	  and	  mean	  differences	  for	  
continuous	  outcomes.	  
	  
Dealing	  with	  missing	  data	  
In	   cases	  of	  missing	  or	   incomplete	   information	  presented	   in	   the	   included	   studies,	  we	   shall	  
contact	  authors	  for	  further	  information.	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Data	  synthesis,	  assessment/investigation	  of	  heterogeneity	  
We	  will	  assess	  clinical	  heterogeneity	  by	  examining	  types	  of	  participants,	  interventions,	  and	  
outcomes	   in	   each	   study.	   Statistical	   heterogeneity	   in	   each	   meta-­‐analysis	   will	   be	   assessed	  
using	   the	   chi-­‐square	   test	   and	   quantified	   using	   the	   I-­‐squared	   statistic.	   If	   studies	   are	  
sufficiently	  homogenous	  (in	  terms	  of	  study	  populations,	  interventions,	  and	  outcomes),	  then	  
we	  will	  pool	  the	  data	  across	  studies	  and	  estimate	  summary	  effect	  sizes	  using	  a	  fixed-­‐effects	  
model;	   	   otherwise,	   we	   will	   use	   the	   random-­‐effects	   model.	   We	   will	   perform	   subgroup	  
analyses	   by	   intervention	   subtypes:	   long	   versus	   short	   messages;	   daily	   versus	   weekly	  
messages;	  short	  weekly	  messages	  versus	  long	  weekly	  messages;	  short	  daily	  messages	  versus	  
long	   daily	   messages;	   and	   two-­‐way	   interactive	   communication	   versus	   one-­‐way	  
communication	   (Horvath	   et	   al.,	   2012)	   (Thirumurthy	   and	   Lester,	   2012,	   Pop-­‐Eleches	   et	   al.,	  
2011).	  We	  will	  also	  stratify	  analysis	  by	  study	  design	  (randomized	  controlled	  separate	  from	  
non-­‐randomized	   studies)	   and	   intervention	   type	   (multiple	   interventions	   involving	   text	  
messaging	   separate	   from	   text	   messaging	   alone).	   Finally,	   we	   will	   use	   the	   grading	   of	  
recommendations	  assessment,	  development,	  and	  evaluation	  (GRADE)	  approach	  (Balshem	  et	  
al.,	   2011)	   to	   assess	   the	  quality	   of	   evidence	   for	   the	  effectiveness	  of	   the	   SMS	   intervention.	  
This	   method	   results	   in	   an	   assessment	   of	   the	   quality	   of	   the	   body	   of	   evidence	   as	   high,	  
moderate,	  low,	  or	  very	  low.	  Evidence	  is	  considered	  of	  high	  quality	  if	  ‘further	  research	  is	  very	  
unlikely	  to	  change	  our	  confidence	  in	  the	  estimate	  of	  effect’;	  and	  moderate	  quality	  if	  ‘further	  
research	   is	   likely	   to	  have	  an	   important	   impact	  on	  our	  confidence	   in	   the	  estimate	  of	  effect	  
and	  may	  change	  the	  estimate’.	   	  Low	  quality	  evidence	  implies	  that	   ‘further	  research	  is	  very	  
likely	  to	  have	  an	  important	  impact	  on	  our	  confidence	  in	  the	  estimate	  of	  effect	  and	  is	  likely	  to	  
change	  the	  estimate’,	  and	  very	  low	  quality	  that	  ‘we	  have	  very	  little	  confidence	  in	  the	  effect	  
estimate’.	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Subgroup	  analyses	  
Several	  subgroup	  analyses	  will	  be	  performed:	   first	   to	  determine	  whether	  the	  study	  design	  
(RCT	  versus	  nonrandomized	  study)	  could	  influence	  the	  results	  of	  the	  meta-­‐analysis;	  second,	  
to	   evaluate	  whether	   the	  model	   of	   the	   statistical	  method	   (random-­‐effects	   vs	   fixed-­‐effects	  
model)	   could	   change	   the	   results,	   and	   third,	   to	   determine	   the	   impact	   of	   excluding	   studies	  
with	   a	   high	   risk	   bias	   on	   the	   results,	   with	   emphasis	   on	   allocation	   concealment,	   blinded	  
outcome	  assessment,	  and	  losses	  to	  follow-­‐up	  (with	  a	  cut	  off	  of	  25%	  loss	  to	  follow-­‐up).	  
	  
Presenting	  and	  reporting	  of	  results	  
	  
Findings	   in	  our	  systematic	  review	  will	  be	  presented	   in	  several	  ways.	  Flow	  diagrams	  will	  be	  
used	   to	   summarise	   the	   study	   selection	   process.	   Funnel	   plots	   will	   be	   used	   to	   assess	  
publication	  bias	   if	  we	   identify	   10	  or	  more	  eligible	   studies.	   The	   kappa	   statistic	   (Landis	   and	  
Koch,	   1977)	   will	   be	   used	   to	   assess	   agreements	   between	   the	   full-­‐text	   screening,	   data	  
extraction	  and	  risk	  of	  bias	  assessment	  by	  the	  two	  authors	  (RK	  and	  ME).	  GRADE	  summary	  of	  
tables	   of	   findings,	   risk	   of	   bias	   tables	   or	   graphs,	   and	   forest	   plots	   will	   also	   be	   used	   where	  
appropriate.	  The	  reporting	  of	  outcomes	  without	  quantitative	  data	  will	  be	  descriptive.	  Lastly,	  




Systematic	   reviews	   draw	   on	   publicly	   available	   data	   and	   do	   not	   directly	   involve	   human	  
subjects,	   and	   therefore	   do	   not	   require	   formal	   ethical	   review	   (Emanuel	   et	   al.,	   2004).	   	   The	  
study	  protocol	  will	   be	   reviewed	  by	   supervisors	  with	  expertise	   in	  methodology	   (systematic	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Expected	  significance	  of	  the	  study	  
	  
The	   findings	   of	   this	   systematic	   review	   will	   have	   implications	   for	   policy,	   practice	   and	  
research.	   We	   will	   discussed	   the	   relevance	   of	   our	   findings	   to	   childhood	   immunisation	  
programmes	   in	  Africa	   in	   the	  decade	  of	  vaccines	  with	  emphasis	  on	  applicability,	  effects	  on	  
equity,	  cost	  implications,	  and	  monitoring	  and	  evaluation.	  
	  
Our	   systematic	   review	  will	   provide	   evidence	   of	   whether	   policy-­‐makers	   can	   adopt	  mobile	  
phone	  text	  messaging	  alone	  or	  in	  combination	  with	  other	  interventions	  in	  efforts	  to	  improve	  
uptake	   of	   vaccines	   in	   national	   immunisation	   programmes.	   It	   will	   also	   inform	   clinic	   or	  
hospital	  managers	  of	  how	  best	  to	  use	  the	  intervention	  to	  improve	  vaccination	  coverage.	  The	  
systematic	   review	  may	   also	   identify	   specific	   considerations	   that	  would	   needs	   to	   be	   taken	  
into	   account	   for	   future	   studies,	   such	   as	   study	   location,	   content	   and	   timing	   of	   messages,	  
whether	  or	  not	  parents	  or	  caregivers	  replied	  to	  text	  messages,	  how	  text	  messages	  were	  sent	  
(automated	   versus	   manual),	   indicators	   for	   immunisation	   programmes,	   variety	   of	   text	  
messages	   sent	   (inclusion	   of	   jokes	   or	   lifestyle	   tips),	   duration	   of	   the	   study,	  whether	   or	   not	  
participants	  were	  provided	  with	  the	  mobile	  handsets,	  and	  sample	  size	  (Karanja	  et	  al.,	  2011).	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Appendix	  1:	  Search strategy 
 
Table	  1.	  	  PubMed	  search	  strategy,	  modified	  as	  needed	  for	  use	  in	  other	  databases	  
Search	   PubMed	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
#1	   (immunization[Mesh])	  OR	  (	  (immunis*	  OR	  immuniz*	  OR	  vaccin*)	  
#2	   (adolescents	  OR	  children	  OR	  teenagers	  OR	  adults)	  
#3	   "SMS"	  OR	  cellphone	  OR	  "mobile	  phone"	  OR	  "text	  messaging"	  OR	  "short	  message	  
service"	  OR	  "text	  reminder"	  
#4	   #1	  AND	  #2	  
#5	   #3	  AND	  #4	  
MeSH,	  medical	  subject	  heading	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  Data	  Extraction	  Form	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Data	  Extraction	  Form	  
Reviewer	  ID	  :	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Study	  ID:	  
	  
Full	  Article	  Title:	  
Citation:	  
Language	  of	  Publication:	  
Type	  of	  study	  
	   yes	   unclear	   If	  no,	  exclude	  
RCT	   	   	   	  
CCT	   	   	   	  
CBA	   	   	   	  
Quasi-­‐randomised	  
trials	  
	   	   	  
Cross-­‐over	  study	   	   	   	  
	  
Trial	  Intervention:	  
	  Was	  the	  intervention	  a	  short	  message	  service	  [sms]to	  remind	  participants	  of	  the	  first	  dose	  of	  
vaccination?	  
yes	   	  
unclear	   	  
If	  no,exclude	   	  
	  
Was	  there	  a	  control	  or	  comparison	  group	  that	  did	  not	  receive	  the	  same	  	  intervention	  ?	  
yes	   	  
unclear	   	  
If	  no,exclude	   	  
	  
Was	  there	  a	  secondary	  message	  [sms]	  sent	  to	  remind	  participants	  to	  come	  back	  if	  first	  visit	  was	  
missed	  to	  assess	  recall	  rate?	  
yes	   	  
unclear	   	  
	   	  
	  
Tick	  as	  appropriate:	  
include	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exclude	   	  
Uncertain-­‐requires	  full	  text	  article	   	  
Pending-­‐study	  still	  in	  progress	   	  
	  






	  Randomization	  method:	  	  
Allocation	  concealment:	  	  
Duration	  of	  trial:	  	  
Duration	  of	  follow	  up:	  	  
	  
Loss	  to	  follow	  up	  
	   Intervention	   Control	   Total	  
Total	  number	  randomized	   	   	   	  
Number	  available	  at	  follow	  up	   	   	   	  
Number	  Loss	  to	  follow	  up	   	   	   	  
Number	  included	  in	  the	  analysis	   	   	   	  
 
 
Was	  analysis	  done	  as	  intention	  to	  treat	  	   Yes	  £	   	   No	  £	   	  	  	  	  	  	  Unclear	  £	  
(Were	  all	  the	  randomised	  participants	  included	  in	  the	  analysis?)	  
 
	   	  




Country	  and	  setting:	  	  	  ______________________________________________________________	  
Developing	  country:	  	  	  Yes	  	  ___	  	  	   No	  ___	  
	  
Disease:	  
Vaccination	  Schedule:	  	  	  
	  
Number	  of	  persons	  in	  trial	  
	   Intervention	   Control	   Total	  
Number	   	   	   	  
%	  of	  Total	   	   	   100%	  
	  
Gender	  	  
	   Intervention	   Control	   Total	  
	   N	   %	   N	   %	   N	   %	  
Male	   	   	   	   	   	   	  
Female	   	   	   	   	   	   	  
Total	   	   	   	   	   	   	  
	  
Age	  	  
	   Intervention	   Control	   Total	  
Mean	  Age	   	   	   	  
	   N	   %	   N	   %	   N	   %	  
<13	  years	   	   	   	   	   	   	  
>13	  years	   	   	   	   	   	   	  
 




Intervention:	  sms	  reminder	  
SMS	   	  
Frequency	   	  
Details	  of	  the	  sms	  
	  
	  
Recall	  sms	  sent	  for	  
unvaccinated	  participants	  
	  
Other	  remarks	   	  
	  
Control	  –usual	  care	  
sms	   	  
Frequency	   	  
Recall	  sms	  sent	  for	  
unvaccinated	  participants	  
	  
Other	  remarks	   	  
 
 
	   	  










2. Primary	  outcomes:	  receipt	  of	  one	  or	  more	  vaccination	  within	  the	  specified	  period	  
	   M	   F	   Total	  
Total	  Number	  SMSs	   	   	   	  
Undeliverable	   	   	   	  
Incorrect	  number	   	   	   	  
Declined	   	   	   	  
Other	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VACCINATION	  COVERAGE	  
Authors’	  definition	  of	  coverage:	  	  	  
	  
Primary	  Outcome	  
	   Intervention	   %	   Control	   %	   Difference	   RRR	  
Total	  SMSs	   	   	   	   	   	   	  
Primary:	  
Number	  vaccinated	  
	   	   	   	   	  	   	  
Age-­‐group	  Breakdown	  
	   /	   	   	   	   	   	  
	   	   	   	   	   	   	  
	   	   	   	   	   	   	  




	   Intervention	   %	   Control	   %	   Difference	   RRR	  
Total	  SMSs	   	   	   	   	   	   	  
Secondary:	  
Recall	  Rate	  
	   	   	   	   	  	   	  
Age-­‐group	  Breakdown	  
	   /	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Background:	  	  	  Low	  vaccine	  coverage	  is	  a	  major	  public	  health	  concern,	  the	  consequences	  of	  
which	   contribute	   to	   around	   1.5	   million	   child	   deaths	   from	   vaccine-­‐preventable	   diseases.	  	  
Thus,	  innovative	  strategies	  to	  rapidly	  increase	  coverage	  and	  recall	  rates	  for	  vaccinations	  are	  
urgently	   required.	   	   Mobile	   text	   messaging	   (or	   short	   messaging	   service,	   SMS)	   has	   the	  
potential	   to	   help	   increase	   vaccination	   coverage	   and	   therefore,	   we	   propose	   to	   conduct	   a	  
review	   of	   the	   current	   best	   evidence	   for	   the	   use	   of	   SMS	   as	   an	   intervention	   to	   promote	  
vaccination	  coverage.	  
Methods:	  	  	  This	  is	  a	  systematic	  review	  of	  the	  effectiveness	  of	  SMS	  in	  improving	  the	  uptake	  
of	  vaccination.	   	  We	  searched	  several	  bibliographic	  databases	  (Pubmed,	  Web	  of	  Knowledge	  
and	   Scopus)	   and	   the	   clinical	   trials	   register	   available	   by	   November	   2013,	   regardless	   of	  
language	   or	   publication	   status.	   Two	   authors	   independently	   screened	   eligible	   studies	   and	  
assessed	   risk	   of	   bias	   in	   included	   studies,	   resolving	   discrepancies	   by	   discussion	   and	  
consensus.	  	  
Results:	   	  Six	  studies	  comprising	  seven	  populations	  with	  a	  total	  of	  12,484	  participants	  were	  
analysed	  to	  investigate	  the	  effects	  of	  SMS	  as	  an	  intervention	  to	  promote	  vaccination	  among	  
adults,	   adolescents	   and	   parents	   or	   caregivers	   of	   children.	   Compared	   with	   participants	  
receiving	  usual	  standard	  of	  care,	  participants	  receiving	  text	  messages	  were	  25%	  more	  likely	  
to	   comply	  with	   vaccination	   (risk	   ratio	   [RR]	   1.25,	   95%	  confidence	   intervals	   [CI]	   1.07,	   1.46).	  
This	  finding	  was	  consistent	  for	  vaccinations	  requiring	  multiple	  visits	  (RR=1.38,	  [95%	  CI	  1.21,	  
1.58])	  as	  well	  as	  across	  all	  age	  categories	  (Non-­‐adult	  vs	  Adult:	  RR=1.29,	  [95%	  CI	  1.04;	  1.60]	  
vs	  RR=1.26,	   [95%	  CI	  1.08,	  1.48]).	   	   Furthermore,	   country	   setting	  did	  not	  affect	   the	  positive	  
findings.	   Where	   studies	   looked	   at	   influenza	   only,	   we	   found	   the	   effect	   was	   significant	   in	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favour	   of	   the	   text	   message	   intervention	   (RR	   1.17,	   [95%	   CI,	   1.03;	   1.33])	   compared	   with	  
diseases	   other	   than	   influenza	   where	   the	   evidence	   indicates	   62%	   increased	   likelihood	   of	  
vaccination	   uptake	   due	   to	   SMS;	   	   however,	   the	   result	  was	   not	   statistically	   significant	   (RR=	  
1.62,	   [95%	  CI,	  0.84;	  3.10]).	   	  The	  quality	  of	  evidence	   in	  this	  systematic	  review	  was	  rated	  as	  
moderate	   using	   the	   GRADE	   approach.	   Sensitivity	   analyses	   revealed	   that	   heterogeneity	  
generally	  had	  a	  negligible	  effect	  on	  the	  findings.	  
Discussion/Conclusion:	  	  	  There	  is	  moderate	  quality	  evidence	  a	  text	  message	  intervention	  is	  
effective	   in	   increasing	   vaccination	   coverage.	   However,	   there	   is	   insufficient	   evidence	   to	  
support	   its	   use	   for	   non-­‐influenza	   vaccines.	   Furthermore	   there	   is	   a	   dearth	   of	   evidence	  
emanating	  from	  low-­‐	  and	  middle-­‐income	  countries.	  	  	  
Keywords:	   	  Vaccine	   coverage,	   vaccination,	  Mobile	   text	  messaging,	   SMS,	   short	   messaging	  
service	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1.	  	  Background	  
Vaccinations,	  when	  given	  at	   the	  most	  sensitive	  developmental	  years	  of	  childhood,	  help	   to	  
promote	   comprehensive	   and	   capable	   immunity,	   enabling	   children	   to	   fight	   off	   certain	  
diseases	   [1,	   2].	   In	   addition,	   vaccinations	   are	   widely	   regarded	   as	   one	   of	   the	   most	   cost-­‐
effective	  public	  health	  interventions	  that	  help	  to	  reduce	  global	  child	  morbidity	  and	  mortality	  
[3,	  4].	  Low	  coverage	  of	  vaccinations	  is	  a	  major	  public	  health	  concern.	  In	  Africa	  alone,	  more	  
than	  seven	  million	  children	  did	  not	  receive	  the	  full	  spectrum	  of	  vaccinations	  recommended	  
before	  reaching	  one	  year	  of	  age	  in	  2009	  [5].	  It	  is	  also	  estimated	  that	  1.5	  million	  children	  died	  
globally	   from	   vaccine-­‐preventable	   diseases	  where	  World	   Health	   Organization	   (WHO)	   pre-­‐
qualified	  vaccines	  were	  available	  [6].	  
	   	  
The	  Global	  Vaccine	  Action	  plan	   (GVAP)	   is	   the	  most	   recently	   launched	  global	   effort	  by	   the	  
WHO	   to	   help	   increase	   vaccination	   coverage.	   The	   GVAP	   has	   set	   a	   target	   that	   by	   2020	  
vaccination	  coverage	  for	  populations	  should	  reach	  90%	  national	  vaccination	  coverage	  and	  at	  
least	  80%	  at	  district	   levels	  utilizing	  national	  vaccination	  programmes	  [7].	   It	   is	  guided	  by	  six	  
principles:	   country	   ownership,	   shared	   responsibility	   and	   partnership,	   equity,	   integration,	  
sustainability,	  and	  innovation	  [8]	  	  
	  
A	  variety	  of	   factors	   impact	  achieving	   low	  coverage	  rates;	  challenges	  such	  as	   immunisation	  
awareness,	  demand	  for	  immunisation,	  level	  of	  trust	  in	  the	  health	  system,	  adequate	  human	  
resources,	   access,	   timeliness	   of	   vaccinations,	   service	   delivery,	   poor	   infrastructure	   and	  
vaccination	   monitoring	   [3].	   	   Vaccination	   coverage	   seems	   to	   be	   lower	   in	   low-­‐income	  
households,	  where	   limited	  access	   to	  health	  education,	   contributes	   to	  poor	  health-­‐seeking	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behaviour	  along	  with	  an	  inability	  to	  improve	  general	  wellbeing	  [1,	  2,	  9].	  Uneducated	  parents	  
therefore	  are	  less	  likely	  to	  understand	  the	  importance	  of	  vaccinating	  to	  prevent	  potentially	  
harmful	   diseases.	   	   In	   light	   of	   these	   obstacles	   to	   vaccination	   coverage,	   the	   strategy	   to	  
improve	   vaccination	   coverage	   needs	   to	   be	   innovative	   as	   alluded	   to	   in	   the	   GVAP,	   well	  
thought	  out	  and	  able	  to	  penetrate	  low	  income	  households	  effectively.	  
	  
Globally,	  mobile	  phone	  use	  is	  rapidly	  increasing,	  with	  an	  estimated	  6.6	  billion	  mobile	  phone	  
subscriptions	  end	  of	  2012	  [10].	  	  In	  addition,	  the	  number	  of	  unique	  mobile	  phone	  subscribers	  
at	  the	  end	  of	  2012	  was	  estimated	  to	  be	  3.2	  billion,	  with	  an	  average	  of	  1.85	  SIM	  cards	  per	  
individual	   and	  mobile	   operators	   are	   including	   inactive	   SIM	   cards	   in	   their	   reported	   global	  
mobile	   phone	   subscription	   totals	   [11].	   However,	   the	   number	   of	   mobile	   phone	   users	   has	  
continued	  to	  increase	  and	  is	  spreading	  to	  the	  most	  remote	  areas	  in	  the	  world.	  	  	  
	  In	   particular,	  mobile	   phone	   text	  messaging	   has	   gained	   popularity	   among	   people	   living	   in	  
low-­‐	  and	  middle-­‐income	  countries	  and	  may	  be	  the	  key	  to	  penetrating	  hard	  to	  reach	  areas	  in	  
the	  developing	  world.	  Text	  messaging	  has	  proven	  to	  be	  a	  cost	  effective	  method	  of	  relaying	  
health	  information	  and	  reminders	  than	  the	  more	  traditional	  methods	  such	  as	  face	  to	  face,	  
phone	   calls,	   pamphlets,	   mail	   and	   email	   [5].	   As	   immunisation	   usually	   requires	   multiple	  
consecutive	  monthly	   visits	   after	   the	   first	   vaccine	  dose	   in	  order	   to	   complete	   the	   schedule,	  
short	  messaging	  service	   (SMS)	  can	  be	  used	  as	  a	   reminder	   for	  an	  upcoming	  visit	  and	  recall	  
when	  a	  visit	  has	  been	  missed	   [1].	   In	  addition,	  an	  SMS	   intervention,	  also	  known	  as	  mobile	  
phone	   text	   messaging,	   can	   be	   delivered	   alone	   or	   bundled	   with	   other	   interventions	   [12].	  	  
Diseases	  that	  have	  used	  mobile	  technology	  successfully	  include	  HIV	  where	  a	  90%	  adherence	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to	   uptake	   of	   anti-­‐retroviral	   medication	   was	   observed	   among	   text	   message	   recipients	  
compared	  with	  a	  40%	  adherence	  in	  the	  control	  group	  [13].	  
An	   earlier	   systematic	   review	   looked	   at	   the	   role	   of	   SMS	   as	   an	   intervention	   for	   promoting	  
adherence	   to	   anti-­‐tuberculosis	   treatment	   and	   found	   that	   in	   two	   of	   the	   studies,	   an	   SMS	  
intervention	  significantly	  improved	  the	  adherence	  to	  tuberculosis	  treatment.	  	  The	  remaining	  
studies	   reported	   no	   evidence	   for	   a	   significant	   effect	   in	   favour	   of	   an	   SMS	   intervention.	  	  
Furthermore,	  the	  authors	  of	  this	  review	  were	  concerned	  with	  the	  lack	  of	  high	  quality	  data	  
and	  rated	  the	  current	  evidence	  as	  reported	  in	  this	  review,	  as	  being	  of	  low	  quality.	  [14]	  	  
	  
In	  another	   review,	  SMS	  was	   reported	   to	   significantly	   improve	  adherence	   to	  appointments	  
and	   antiretroviral	   therapy,	   short-­‐term	   smoking	   quit	   rates,	   and	   selected	   clinical	   and	  	  
behavioral	   outcomes.	   [15]	   	   There	   is	   also	   some	   indication	   that	   SMS	   interventions	   could	  
change	  behavior	   in	  weight	   loss	   reduction,	   although	   results	  were	  not	   significant.[16]	   	   SMS	  
interventions	   have	   been	   successful	   in	   optimizing	   clinic	   time	   and	   at	   improving	   the	  
relationship	  between	  post-­‐operative	  patients	   in	   reducing	  clinic	  visits	  and	  drainage	   time	  of	  
wounds.	  [17]	  	  SMS	  has	  also	  had	  a	  beneficial	  effect	  in	  diabetes	  patients	  where	  it	  was	  shown	  
to	  have	  better	  health	  outcomes	  and	  significant	  improvement	  in	  the	  SMS	  group	  in	  relation	  to	  
blood	  results	  analyzing	  HbA1c	  and	  plasma	  lipids.	  [18]	  
	  
In	  order	  to	  understand	  the	  evidence	  available	  where	  a	  text	  message	  intervention	  was	  used	  
to	   increase	   the	   uptake	   of	   vaccinations,	  we	   conducted	   a	   systematic	   review	   of	   the	   current	  
best	  evidence	  for	  the	  use	  of	  mobile	  phone	  text	  messaging	  to	  improve	  vaccination	  coverage.	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2.	  	  Methods	  
The	   methods	   for	   this	   review	   is	   largely	   based	   on	   the	   Cochrane	   Handbook	   of	   Systematic	  
Reviews	  for	  Interventions	  [19].	  
	  
2.1	  Criteria	  for	  considering	  studies	  for	  this	  review	  
2.1.1	  Type	  of	  studies	  
We	  included	  all	  randomized	  controlled	  trials	  and	  non-­‐randomized	  controls	   if	  a	  comparison	  
group	   was	   included	   in	   the	   study,	   which	   assessed	   using	   a	   text	   message	   intervention	   to	  
promote	  the	  uptake	  of	  a	  vaccine	  as	  a	  primary	  or	  secondary	  outcome.	  
	  
2.1.2	  Type	  of	  participants	  
Participants	  were	  children	  or	  caregivers,	  adolescents,	  adults	  including	  pregnant	  women	  that	  
were	  drawn	  from	  a	  community-­‐based	  setting.	  
	  
2.1.3	  Types	  of	  interventions	  
Text	   messages	   that	   delivered	   a	   reminder	   to	   be	   vaccinated,	   educational	   informational	   or	  
information	   regarding	   the	  vaccine	  availability	  and	  clinic	  details	  were	  considered	  as	  a	  valid	  
text	  message	   intervention.	  We	   excluded	   studies	  where	   a	   comparison	   group	   did	   not	   form	  
part	   of	   the	   analysis.	   Some	   studies	   compared	   the	   intervention	   to	   usual	   care	   and	   others	  
offered	  both	  the	  control	  and	  intervention	  group	  a	  text	  message;	  one	  with	  only	  educational	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information	   and	   the	   other	   both	   educational	   information	   and	   vaccination	   reminders	   and	  
clinic	  availability	  respectively.	  
2.1.4	  Types	  of	  outcome	  measures	  
The	   primary	   outcome	   for	   this	   review	   was	   uptake	   of	   vaccination.	   	   For	   the	   secondary	  
outcome,	   we	   considered	   recall	   rate	   in	   persons	   who	   had	   previously	   missed	   their	  
vaccinations.	  	  
	  
2.1.5	  Search	  methods	  for	  the	  identification	  of	  studies	  
We	   developed	   a	   highly	   sensitive	   search	   strategy	   combining	   key	   terms	   that	   may	   indicate	  
uptake	  of	  vaccination	  via	  an	  text	  message	  intervention(eg.	  text	  message,	  sms,	  cell,	  mobile,	  
vaccination	  and	  phone)	  with	  the	  MeSH	  headings	  “vaccinat*”	  and	  “text	  message	  or	  sms”	  and	  
search	   terms	   for	   all	   existing	   randomized	   and	   non-­‐randomised	   trials.	   Two	   investigators	  
searched	  independently	  (RK	  and	  DB),	  in	  duplicate	  the	  following	  databases	  (from	  inception	  to	  
October	  2013.):	  MEDLINE	  via	  PubMed,	  EMBASE,	  Scopus,	  Web	  of	  Knowledge,	  and	  Cochrane	  
CENTRAL.	  We	  also	  conducted	  a	  search	  within	  clinical	   trials.gov	   to	  ascertain	   if	  any	  ongoing	  
studies	  have	  been	  completed	  before	  conclusion	  of	  this	  systematic	  review	  [20].	  	  The	  search	  
strategy	  used	  for	  searching	  the	  PubMEd	  database	  is	  detailed	  in	  Table	  1.	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Table	  1.	  	  PubMed	  search	  strategy,	  modified	  as	  needed	  for	  use	  in	  other	  databases	  
Search	   PubMed	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
#1	   (immunization[Mesh])	  OR	  (	  (immunis*	  OR	  immuniz*	  OR	  vaccin*)	  
#2	   (adolescents	  OR	  children	  OR	  teenagers	  OR	  adults)	  
#3	   "SMS"	  OR	  cellphone	  OR	  "mobile	  phone"	  OR	  "text	  messaging"	  OR	  "short	  message	  
service"	  OR	  "text	  reminder"	  
#4	   #1	  AND	  #2	  
#5	   #3	  AND	  #4	  
MeSH,	  medical	  subject	  heading	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2.2	  	  Study	  Selection	  
Using	   a	   predefined	   protocol	   (available	   from	   corresponding	   author	   on	   request),	   two	  
investigators	   (RK,	   DB)	   worked	   independently	   for	   1	   month,	   in	   duplicate,	   screening	   all	  
abstracts	  and	  obtaining	  the	  full	  text	  	  articles	  that	  indicated	  that	  a	  text	  message	  intervention	  
was	   used	   to	   improve	   the	   uptake	   of	   a	   vaccination.	   After	   obtaining	   full	   reports	   of	   the	  
candidate	  studies	  (either	  in	  full	  peer-­‐reviewed	  publication,	  conference	  abstract	  or	  non	  peer-­‐
reviewed	   article)	   	   the	   same	   reviewers	   independently	   assessed	   eligibility.	   	   Reviewers	  were	  
not	  blinded	  to	  study	  authors,	  study	  conclusions	  and	  outcomes	  as	  blinding	  has	  been	  shown	  
to	  have	  little	  effect	  on	  systematic	  review	  results	  [21].	  	  	  	  	  	  	  	  	  	  	  
	  To	   obtain	   full	   information	   regarding	   	   conference	   abstracts	   and	   registered	   trials,	   we	  
attempted	  contact	  with	  all	  study	  authors	  for	  full	   information	  through	  email	  and	  telephone	  
communication.	  After	  all	  potentially	  relevant	  full-­‐text	  articles	  and	  abstracts	  were	  identified,	  
we	  consulted	  as	  a	  team	  of	  (RK,	  DB)	  to	  achieve	  consensus	  regarding	  eligibility	  and	  consulted	  
an	  arbitrator	  (ME)	  for	  adjudication.	  
	  
2.3	  	  Data	  extraction	   	  
During	   November	   2013,	   RK	   and	   DB	   independently	   extracted	   data	   in	   duplicate,	   using	   a	  
standardized	  pre-­‐piloted	  form.	  Data	  collected	  included	  information	  about	  the	  study	  setting,	  
study	   populations,	   sample	   size,	   and	   methods	   of	   vaccination	   uptake	   as	   a	   result	   of	   a	   text	  
message	   intervention.	   We	   considered	   different	   measures	   of	   vaccination	   uptake	   as	   the	  
primary	  outcome.	  Five	  studies	  measured	  the	  outcome	  using	  online	  vaccination	  records	  and	  
one	   study	   used	   self-­‐reporting	   as	   the	  measure.	   Our	   primary	   endpoint	  was	   the	   number	   of	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individuals	   in	   the	   exposure	   and	   control	   groups	   achieving	   vaccination	   uptake	   at	   the	   study	  
endpoint.	   We	   entered	   the	   data	   into	   an	   electronic	   database	   such	   that	   duplicate	   entries	  
existed	  for	  each	  study;	  when	  the	  two	  entries	  did	  not	  match,	  we	  reached	  consensus	  through	  
discussion.	  We	   considered	   study	  quality	   according	   to	   reporting	  of	   randomization	  method,	  
adjustment	   of	   experimental	   confounders,	   allocation	   concealment,	   blinding	   of	   analysts,	  
objectivity	   of	   outcome	  measures,	   use	   of	   intention-­‐to-­‐treat	   analysis	   and	   loss	   to	   follow-­‐up	  
larger	  than	  20%.	  
	  
2.4	  Data	  analysis	  
RK	   and	   ME	   conducted	   all	   statistical	   analyses.	   We	   calculated	   the	   Relative	   Risk	   (RR)	   and	  
appropriate	   95%	   Confidence	   Intervals	   (CIs)	   of	   the	   primary	   outcomes	   according	   to	   the	  
number	  of	  events	  reported	  in	  the	  original	  studies	  or	  sub	  studies	  as	  intent-­‐to-­‐treat	  analyses.	  
Where	   studies	   did	   not	   report	   intent-­‐to-­‐treat,	   we	   analysed	   outcomes	   as	   all-­‐patients	  
randomized.	  	  
We	  pooled	  studies	  as	  an	  analysis	  of	  vaccination	  uptake	  using	  the	  random	  effects	  method,	  
which	  recognizes	  and	  anchors	  studies	  as	  a	  sample	  of	  all	  potential	  studies,	  and	  incorporates	  
an	  additional	  between-­‐study	  component	   to	   the	  estimate	  of	  variability	   [22].	  We	  calculated	  
the	  I2	  statistic	  for	  each	  analysis	  as	  a	  measure	  of	  the	  proportion	  of	  the	  overall	  variation	  that	  is	  
attributable	   to	   between-­‐study	   heterogeneity	   [23],	   and	   calculated	   the	   appropriate	   I2	  
confidence	  intervals.	  We	  imputed	  the	  experimental	  and	  control	  event	  rates	  from	  our	  meta-­‐
analysis	  and	  applied	  a	  95%	  power	  at	  the	  5%	  significance	  level.	  All	  outcomes	  are	  reported	  as	  
intention-­‐to-­‐treat.	  Forest	  plots	  are	  displayed	  for	  each	  vaccination	  uptake	  analysis,	  showing	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individual	   study	   proportions	   with	   95%	   CIs,	   and	   the	   overall.	   All	   p-­‐values	   are	   exact	   and	   2-­‐
sided.	   We	   considered	   a	   p-­‐value	   <0.05	   to	   be	   significant.	   Analyses	   were	   conducted	   using	  
Revman	   5.1	   statistical	   software	   (http://ims.cochrane.org/RevMan).	   	   Subgroup	   analyses	  
were	   performed	   to	   evaluate	   the	   effect	   of	   study	   design	   and	   conduct,	   type	   of	   intervention	  
and	  participants	  as	  well	  as	  method	  of	  confirmation	  of	  vaccination	  uptake.	  
	  
2.5	  Role	  of	  the	  Funding	  Source	  
We	  did	  not	  receive	  funding	  for	  this	  study.	  
	  
2.6	  Ethics	  
Systematic	   reviews	   draw	   on	   publicly	   available	   data	   and	   do	   not	   directly	   involve	   human	  
subjects,	  and	  therefore	  do	  not	  require	  formal	  ethical	  review	  [24].	   	  The	  study	  protocol	  was	  
reviewed	  by	  supervisors	  with	  expertise	   in	  the	  systematic	  review	  method	  and	  submitted	  to	  
the	  University	  of	  Cape	  Town	  Departmental	  Research	  Committee	  for	  approval.	  
	  
	   	  
	   	  





3.1	  Study	  flow	  and	  description	  of	  studies	  
A	   flow	  diagram	  of	   studies	   included	   in	   the	  analysis	   is	  detailed	   in	   Figure	  1.	   	   From	  the	   initial	  
search,	  we	  identified	  348	  titles	  from	  the	  various	  databases.	  	  After	  removing	  duplicates	  and	  
examining	   titles,	   76	   articles	   were	   included.	   	   Of	   these,	   10	   studies	   were	   deemed	   as	   being	  
potentially	  relevant	  with	  perfect	  agreement	  between	  reviewers.	  	  Following	  a	  review	  of	  the	  
abstracts,	  six	  articles	  remained	  eligible	  for	  inclusion.	  	  All	  full	  text	  papers	  and	  abstracts	  were	  
published	  in	  English.	  	  Five	  studies	  were	  conducted	  within	  the	  USA	  while	  the	  remaining	  study	  
was	   conducted	   in	   China.	   	   	   (Table	   2	   summarizes	   the	   characteristics	   of	   the	   six	   included	  
studies).	  	  Detailed	  information	  on	  included	  studies	  are	  provided	  in	  Appendix	  1.	  	  	  
Four	  studies	  were	  excluded	  for	  the	  following	  reasons:	  	  no	  comparison	  group	  [25],	  an	  earlier	  
version	   of	   an	   already	   included	   study	   [26],	   non-­‐community	   setting	   [27]	   and,	   conference	  
presentation	   lacking	   sufficient	   detail	   [28].	   (Details	   are	   provided	   in	   Table	   3,	   “Table	   of	  
Excluded	  Studies”).	  	  
Of	   the	   15	   trials	   rendered	   by	   a	   search	   in	   ClinicalTrials.gov	   [20],	   13	  matched	   our	   inclusion	  
criteria.	   	   From	   these,	   two	   had	   already	   been	   included	   as	   published	   articles	   [29,	   30],	   (See	  
Table	  4:	  	  NIH	  Clinical	  trials	  Register).	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Table	  2:	  	  	  Characteristics	  of	  Included	  Studies	  
	  
Study	   Setting,	  Country	   Age	  Range	  of	  
those	  receiving	  
vaccinations	  
%	  male	   No	  of	  
participa
nts	  
Disease	   Intervention	  
/	  Control	  
Primary	  Outcome	  
Ahlers-­‐Schmidt,	  2012	   Academic	  Centres,	  USA	   2-­‐6	  months	   83.33%	   90	   	  2,	  4,	  6	  month	  
infant	  vaccines	  
SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Chai,	  2013	   Clinic	  population,	  China	   18-­‐>60	  yrs	   48%	   1998	   	  H1N1	  influenza	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Kharbanda,2011	   Clinic	  population,	  USA	   9-­‐20	  yrs	   Only	  female	   1512	   HPV	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Moniz,	  2013	   Medical	  centres,	  USA	   14-­‐50	  yrs	   Only	  female	   216	   	  Influenza	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Stockwell	  b	  
(adolescents),2012	  
Clinic	  population,	  USA	   11-­‐18	  yrs	   42%	   361	   	  MCV4/Tdap	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Stockwell	  b	  
(paediatric),2012	  
Clinic	  population,	  USA	   7-­‐22	  months	   50%	   174	   Hib	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
Stockwell(a),	  2012	   hospital	  population,USA	   6	  months-­‐18	  yrs	   49%	   9213	  	  	  	  	  	  	  	   	  influenza	   SMS	  /	  SOC	   Receipt	  of	  vaccine	  
N,	  number;	  	  SMS,	  short	  message	  service;	  	  SOC,	  standard	  of	  care;	  	  yrs,	  years;	  HPV,	  human	  papilloma	  virus;	  Hib,	  Heamophilus	  Influenzae	  
	  




TABLE	  3:	  	  Characteristics	  of	  Excluded	  studies	  
Study	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Reason	  for	  exclusion	  
Vilella,	  2004	   non-­‐community	  based	  setting	  
Wakadha,	  2013	   no	  comparison	  group	  
Kharbanda,	  2011	   early	  version	  of	  the	  same	  study	  
Russel	  2012	   conference	  presentation	  	  with	  limited	  data	  
	  
Participants	  within	  studies	  were	  exclusively	  adults	  [31,	  32],	  adolescents	  [26]	  and	  infants	  [29]	  
while	  two	  studies	  included	  both	  infants	  and	  adolescents	  [30,	  33]	  .	  	  One	  study,	  however,	  [33]	  
analysed	  adolescent	  and	  paediatric	  populations	  separately.	  Therefore,	  from	  the	  six	  studies,	  
7	  populations	  are	  analysed.	   	   	  Kharbanda	  et	  al	  had	  two	  control	  groups,	  an	  “opt-­‐out”	  and	  a	  
historical	  control	  group	  comprising	  308	  and	  1080	  participants	  respectively	  [26].	  	  
Vaccinations	   included	   those	   against	   human	   papilloma	   virus	   [26],	   influenza	   [30-­‐33],	  
meningococcal	   (MCV4)	   or	   tetanus/diptheria/accellular	   pertussis	   (Tdap)	   [33].	   	   One	   study	  
comprised	  routine	  infant	  immunisations	  [29].	  	  Two	  studies	  [26,	  33]	  	  incorporated	  follow-­‐up	  
doses	   for	   completion	   of	   the	   vaccination	   schedule;	   the	   first	   vaccination	   uptake	   data	   from	  
these	  studies	  were	  pooled	  with	  those	  from	  the	  rest	  of	  the	  studies.	  	  One	  study	  relied	  on	  self-­‐
reported	   data,	   [31]	   while	   the	   rest	   used	   online	   vaccination	   records	   to	   verify	   vaccination	  
uptake.
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Table	  4:	  	  	  	  NIH	  Clinical	  Trials	  Register	  
Title	   Trial	  number	   Status	   Include/exclude	  	   If	  published,	  citation	  
Text	  Message	  Reminder-­‐Recalls	  For	  Early	  Childhood	  Vaccination	   NCT00076804	   Active,	  not	  
recruiting	  
Exclude	   	  
Adult	  Influenza	  Vaccination	  Text	  Message	  Reminders	  	  
	  
NCT01942824	   Not	  yet	  
recruiting	  
Exclude	   	  
TextFluenza:	  Using	  Technology	  To	  Promote	  Flu	  Vaccination	  In	  Underserved	  Maternal	  
And	  Child	  Populations	  	  
NCT01146912	   Completed	   Include	   Stockwell,	  JAMA,	  2012	  
Pilot	  Text	  Message	  for	  Influenza	  Vaccination	   NCT01761734	   Active,	  not	  
recruiting	  	  
Exclude	   	  
Effectiveness	  of	  SMS	  (Short	  Message	  Service)	  Text	  Messaging	  in	  Increasing	  Adherence	  
to	  Gardasil	  	  
Vaccine	  Health	  Literacy	  Related	  Text	  Message	  Reminders	  to	  Increase	  Receipt	  of	  













Adolescent	  Vaccination	  in	  the	  Medical	  Home:	  Established	  and	  Innovative	  Strategies	   NCT01577979	   Enrolling	  by	  
invitation	  	  
Exclude	   	  
Influenza	  and	  Text	  Messaging	  in	  Pregnancy	   NCT01248520	   Active,	  not	  
recruiting	  	  
Exclude	   	  
PregText:	  Feasibility	  of	  Monitoring	  Influenza	  Vaccine	  Safety	  in	  Pregnant	  Women	  Using	  
Text	  Messaging	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Text	  Messaging	  Reminders	  for	  Influenza	  Vaccine	  in	  Primary	  Care	   NCT01892631	   Not	  yet	  
recruiting	  	  
Exclude	   	  
Text	  Reminders	  for	  Immunization	  Compliance	  in	  Kids	  (TRICKS)	  Pilot	  Study	   NCT00367172	   Completed	   Include	   Ahlers-­‐Schmidt,	  
Vaccine,	  2012	  
Text	  Reminders	  to	  Immunize	  in	  a	  Managed	  Care	  Organization	  	   NCT01806714	   Recruiting	   Exclude	   	  
The	  Efficacy	  of	  Reminders	  to	  Complete	  HPV	  Series	  	   NCT01731496	   Recruiting	  	   Exclude	   	  
Real-­‐time	  Influenza	  Vaccine	  Surveillance	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The	   SMS	   interventions	   comprised	   reminders	   of	   appointment	   dates	   [26,	   29,	   30,	   33],	  	  
(adolescent	  and	  paediatrics)	  or	   indications	  of	  the	  availability	  of	  the	  vaccine	  at	  a	  local	  clinic	  
[30-­‐33].	   	  Three	  studies	   incorporated	  an	  additional	  educational	  component	  within	   the	  SMS	  
[30-­‐32].	  	  None	  of	  the	  studies	  analysed	  the	  results	  for	  recall	  rates	  and	  thus,	  we	  were	  unable	  
to	  provide	  results	  for	  our	  secondary	  outcome.	  
	  
3.2	  Assessment	  of	  Risk	  of	  Bias	  in	  included	  studies	  
Five	   studies	   were	   randomised	   controlled	   trials	   (RCTs)	   and	   reported	   the	   randomisation	  
method;	  allocation	  concealment	  was	  unclear	  across	  all	  but	  one	  study	  [32].	   	  The	  remaining	  
study	   incorporated	   non-­‐randomised	   enrolment	   of	   clinic	   attendees	   [26].	   	   	   Three	   studies	  
reported	   blinding	   of	   study	   analysts	   or	   the	   researchers	   [30-­‐32]	   ,	   while	   the	   remainder	  
provided	   insufficient	   detail	   as	   regards	   blinding.	   	   Despite	   statements	   to	   the	   contrary,	   only	  
two	  studies	  reported	  intention-­‐to-­‐treat	  analyses	  [26,	  33].	   	  All	  the	  studies	  provided	  reasons	  
for	   loss-­‐to-­‐follow	   up	   which	   included:	   	   disconnected/wrong	   number,	   relocation,	   excluded	  
from	  analysis	   as	  participants	  were	  vaccinated	  prior	   to	   randomisation,	  did	  not	   receive	   text	  
messages,	   terminated	   pregnancies,	   did	   not	   respond	   to	   post-­‐SMS	  messaging	   survey.	   	   The	  
Cochrane	  Collaboration	  tool	  for	  assessing	  study	  quality	  is	  presented	  in	  Figure	  2.	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Figure	  2:	  	  Risk	  of	  bias	  summary	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3.3 Quantitative Data Synthesis 
 
3.3.1	  Uptake	  of	  vaccination	  in	  all	  included	  studies(Figure	  3)	  
When	  we	  pooled	  all	   the	  studies	  that	  reported	  our	  primary	  outcome	  of	  vaccination	  uptake	  
(n=12484)	  as	  an	  analysis	  of	  text	  message	  intervention	  compared	  with	  usual	  care,	  we	  found	  a	  
significant	  effect	   for	  vaccination	  uptake	   (risk	   ratio	   (RR)=1.25	   [95%	  confidence	   interval	   (CI),	  
1.07;	  1.46]).	   	   Substantial	  heterogeneity	  was	  also	  detected	   (p	  =	  0.03,	   I2	  =	  75%).	  Because	  of	  
this,	  the	  result	  of	  this	  analysis	  should	  be	  interpreted	  with	  caution	  and	  not	  be	  considered	  a	  
definitive	  statement..	  	  	  
	  
	  
Figure	  3:	  	  Uptake	  of	  vaccination	  	  
	  
One	   study	   presented	   an	   additional	   analysis	   using	   a	   historical	   control	   cohort	   [26].	   	   We	  
excluded	   this	   scenario	   from	   the	   analysis	   above,	   given	   the	   likelihood	   of	   selection	   bias;	  	  
nevertheless,	   including	   the	   historical	   cohort	   provided	   similar	   results	   with	   a	   pooled	  
significant	   effect	   favouring	   SMS	   (RR=1.28	   [95%	   CI,	   1.10;	   1.48]).	   	   Heterogeneity	   remained	  
significantly	  high	  [I²	  =	  77%].	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3.3.2	  Type	  of	  vaccination	  (Figure	  4)	  
The	   overall	   significant	   effect	   of	   SMS	   messages	   favouring	   the	   uptake	   of	   vaccination	   was	  
consistent	  when	   conducting	   a	   subgroup	   analysis	   of	   the	   four	   studies	   of	   influenza	   vaccines	  
comprising	  adults	  and	  paediatric	  communities:	   	  participants	   receiving	  SMS	  messages	  were	  
more	  likely	  to	  take	  up	  the	  vaccination;	  this	  was	  a	  significant	  effect	  (RR=1.17	  	  p=0.02	  [95%	  CI,	  
1.03;	  1.33]);	  	  mild	  heterogeneity	  [I²	  =	  39%	  p=0.01].	  	  In	  studies	  reporting	  vaccination	  for	  other	  
diseases	  the	  results	  were	  heterogenous	  	  and	  insignificant	  	  (RR=1.62	  [95%	  CI,	  0.84;	  3.10]).	  
	  
	  
Figure	  4:	  Type	  of	  vaccination	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3.3.3	  Multiple	  visit	  vaccinations	  (Figure	  5)	  
“Two	  studies	  required	  patients	  to	  have	  triple	  doses	  within	  the	  vaccine	  schedule.	   	   	  Overall,	  
significant	  heterogeneity	  was	  evident	  [I2=92%]”	  	  
	  
Figure	  5:	  	  Multiple	  visit	  vaccinations	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3.3.4	  Type	  of	  study	  design	  (Figure	  6)	  
Five	   of	   the	   studies	   included	  were	   RCTs,	   and	   showed	   significant	   heterogeneity	   across	   the	  
studies	  [I²	  =	  69%].	  	  Only	  one	  study	  was	  a	  non	  RCT	  and	  showed	  a	  significant	  effect	  (RR=1.54,	  [95%	  
CI,	  1.23;	  1.92]).	  	  	  	  
	  
	  
Figure	  6:	  Type	  of	  study	  design	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3.3.5.	  Age	  categories	  (Figure	  7)	  
Two	   studies	   consisted	   only	   of	   adults	   receiving	   vaccines	  which,	  when	  pooled,	   showed	   a	   significant	  
effect	   for	   the	   intervention	   (RR=	   1.26	   [95%	   CI,	   1.08;	   1.48])	   with	   no	   heterogeneity	   [I2	   =	   0%].	   	   The	  
remaining	   five	   populations	   comprised	   parents	   and	   caregivers	   of	   infants	   and	   adolescents	   showed	  
significant	  heterogeneity	  was	  present	  [I2	  	  =	  81%],	  therefore	  the	  results	  could	  not	  be	  pooled.	  	  	  	  	  
	  
	  
Figure	  7:	  Age	  categories	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3.3.6	  Blinding	  (Figure	  8)	  
For	   interest,	   we	   considered	   the	   effect	   of	   blinding	   on	   outcome.	   Three	   studies	   reported	   on	   their	  
blinding	  method:	  	  where	  blinding	  was	  reported,	  we	  found	  a	  significant	  pooled	  effect	  (RR=1.15	  [95%	  
CI,	  1.02;	  1.29],	  I²	  =	  38%).	  	  In	  contrast,	  In	  the	  four	  populations	  where	  blinding	  was	  not	  reported,	  no	  




Figure	  8:	  Blinding	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3.3.7	  	  Method	  for	  assessing	  Outcomes	  (Figure	  9)	  
In	   the	   five	   studies	   where	   objective	   assessment	   (e.g.	   online	   verification)	   of	   vaccination	  
uptake	  was	   used,	   the	   pooled	   estimate	   showed	   significant	   heterogeneity	   between	   studies	  	  
[I²	   =	   77%].	  One	   study	   employing	   self-­‐reporting	   to	   obtain	   participants’	   data,	   showed	   a	   significant	  




Figure	  9:	  	  	  Method	  for	  Assessing	  Outcomes	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3.3.8	  Country	  setting	  (Figure	  10)	  
Five	   studies	   were	   conducted	   in	   the	   USA	   which,	   when	   pooled,	   showed	   significant	  
heterogeneity	   	  between	   the	   studies	   [I²	   =	  77%].	   	   Similarly,	   the	   single	   study	   conducted	   in	  a	  
developing	  country	  setting,	  viz.	  China,	  also	  found	  a	  significant	  effect	  for	  SMSs	  promoting	  vaccine	  
uptake	  (RR=1.29,	  [95%	  CI,	  1.09;	  1.54]).	  	  	  
	  
	  
Figure	  10:	  	  Country	  setting	  
	  
	  
3.3.9	  Summary	  of	  Subgroup	  analysis	  
We	  did	  not	   find	  any	   important	  changes	   in	  our	  estimates	  when	  we	   investigated	  the	  effect	  of	   study	  
design	  and	  method	  of	  assessment	  of	  outcomes.	   	  However,	  the	  quantitative	  effect	  amongst	  studies	  
not	   reporting	   blinding	   yielded	   a	   non-­‐significant	   estimate	   (RR=1.65	   [95%	   CI,	   0.93;	   2.92])	   with	  
significant	  heterogeneity	  (I2	  =	  92%).	  	  	  In	  addition,	  we	  did	  not	  find	  any	  changes	  in	  our	  overall	  estimate	  
when	  using	  the	  fixed-­‐effects	  method	  (data	  not	  shown).	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4.	  	  Discussion	  
4.1	  Summary	  of	  findings	  
	  
In	  this	  review,	  six	  studies	  comprising	  seven	  populations	  with	  a	  total	  of	  12,484	  participants	  
were	  analysed	  to	  investigate	  the	  effects	  of	  SMS	  as	  an	  intervention	  to	  promote	  vaccination	  
among	  adults,	  adolescents	  and	  parents	  or	  caregivers	  of	  children.	   	  Overall,	   studies	   showed	  
heterogeneity,	   thus	   not	   making	   it	   possible	   to	   compare	   usual	   standard	   of	   care	   with	   text	  
messaging	   for	   compliance	   with	   vaccination	   schedules.	   However,	   when	   considering	   adults	  
only	  (n=2	  studies),	  SMS	  significantly	  improved	  vaccination	  uptake	  by	  26%	  (RR=1.26,	  [95%CI,	  
1.08;1.48],	  p=0.004).	   	  Among	  the	  studies	  on	   influenza	   (n=4),	   there	  was	  a	  significant	  effect	  
(RR=1.17,	   [95%CI,	  1.03;1.33],	  p=0.02).	   	  Concerning	  type	  of	  disease,	  however,	   the	  evidence	  
for	   SMS	   interventions	   resulting	   in	   a	   62%	   increased	   likelihood	   of	   vaccination	   for	   diseases	  
other	  than	  influenza,	  was	  not	  statistically	  significant.	  	  
4.2	  	  Quality	  of	  the	  evidence	  
	  
We	  used	  the	  GRADE	  approach	  to	  assess	  the	  level	  of	  confidence	  to	  be	  placed	  on	  the	  evidence	  
for	  the	  effects	  of	  SMS	  on	  vaccination	  coverage	  [34]	  .	  This	  method	  results	  in	  an	  assessment	  
of	  the	  quality	  of	  a	  body	  of	  evidence	  as	  high,	  moderate,	   low,	  or	  very	  low.	  	   In	  five	  of	  the	  six	  
included	   studies	   the	   method	   of	   allocation	   concealment	   was	   unclear.	   This	   led	   us	   to	  
downgrade	  the	  quality	  of	  the	  evidence	  from	  high	  to	  moderate.	  Moderate	  quality	  evidence	  
implies	   the	  pooled	   effect	   estimate	   found	   in	   this	   review	  provides	   a	   good	   indication	  of	   the	  
likely	  effect	  of	  SMS	  on	  vaccination	  coverage.	  Although	  moderate	  quality	  evidence	  provides	  a	  
good	  basis	  for	  making	  a	  decision	  about	  whether	  to	  implement	  an	  intervention,	  monitoring	  
of	   the	   impact	   is	   likely	   to	   be	   needed	   and	   impact	   evaluation	   may	   be	   warranted	   if	   it	   is	  
implemented.	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4.3	  	  Strengths	  and	  Limitations	  
	  
The	   main	   strength	   of	   this	   review	   lies	   in	   our	   adherence	   to	   international	   standardised	  
guidelines	   on	   the	   conduct	   and	   reporting	  of	   systematic	   reviews	   [19].	   	   Five	   of	   the	   included	  
studies	  were	  RCTs	  and	  the	  remainder,	  a	  site-­‐based	  intervention	  study	  	  [26].	  The	  data	  were	  
all	  published	  data	  in	  peer-­‐reviewed	  journals	  and	  did	  not	  appear	  to	  have	  selective	  reporting	  
biases.	  The	  majority	  of	  the	  studies	  also	  obtained	  their	  data	  from	  online	  vaccination	  records	  
providing	  us	  with	   very	  high	  quality	  objective	  data.	   	  Although	   conducted	  predominantly	   in	  
the	   USA,	   most	   of	   the	   settings	   were	   community-­‐based	   clinics	   serving	   the	   lower	   socio-­‐
economic	   areas;	   thus	   it	   is	   reasonable	   to	   generalize	   the	   findings	   from	   this	   review	   to	  
communities	  within	  countries.	  
Our	  review	  should	  be	  evaluated	  with	  the	  following	  limitations	  in	  mind.	   	  First,	  although	  our	  
review	   drew	   from	   an	   extensive	   search	   and	   was	   not	   limited	   by	   language,	   conference	  
proceedings	  were	  not	   searched.	   Therefore,	   it	   is	   possible	   that	   additional	   information	   from	  
conference	  proceedings	  not	  leading	  to	  publication	  was	  missed.	  	  Second,	  we	  were	  only	  able	  
to	   find	  a	  single	  study	  emanating	   from	  a	   resource-­‐limited	  country.	   	  Thus,	  more	  studies	  are	  
required	  from	  such	  areas	  in	  order	  to	  increase	  the	  evidence.	  	  It	  is	  unclear	  how	  representative	  
the	   participants	   recruited	   in	   the	   studies	   were	   compared	   with	   those	   worldwide	   receiving	  
vaccinations.	  	  A	  third	  limitation	  relates	  to	  the	  moderate	  quality	  of	  the	  data.	  We	  were	  unable	  
to	   identify	   adequate	   allocation	   concealment	   in	   five	   of	   the	   studies,	   while	   one	   study	   was	  
unclear	  regarding	  random	  sequence	  generation.	  	  Furthermore,	  two	  studies	  did	  not	  provide	  
complete	   outcome	   data,	   thus	   increasing	   attrition	   bias	   and	   one	   study	   employed	   selective	  
reporting,	  and	  therefore	  increasing	  the	  risk	  of	  reporting	  bias.	  	  More	  high	  quality	  data	  would	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aid	  in	  strengthening	  recommendations	  for	  successful	  use	  of	  an	  SMS	  intervention	  to	  improve	  
vaccination	  coverage.	  	  
	  
4.4	  	  Comparison	  with	  existing	  literature	  
To	   our	   knowledge	   this	   is	   the	   first	   systematic	   review	   of	   SMS	   interventions	   for	   improving	  
immunisation	   coverage.	   	   The	   evidence	   provided	   for	   the	   success	   of	   text	   messaging	   in	  
achieving	  desired	  outcomes	   is	   in	  keeping	  with	  those	  present	   in	  another	  review	  comprising	  
two	   studies	   that	   assessed	   the	   effects	   of	   text	  messaging	   in	   promoting	   adherence	   to	   anti-­‐
retroviral	  therapy	  (ARV)	  in	  HIV	  patients	  [36].	  	  Text	  messaging	  was	  also	  shown	  to	  be	  effective	  
in	   71%	   of	   studies	   involving	   non-­‐vaccination	   related	   conditions.[37]	   	   Similarly,	   SMS	  
interventions	  have	  been	  shown	  to	  promote	  medication	  adherence	  in	  HIV,	  contraception	  and	  
smoking	  cessation.	  [38]	  	  A	  review	  looking	  at	  interventions	  to	  increase	  influenza	  vaccination	  
among	   healthcare	   workers	   in	   hospitals	   found	   that	   a	   reminder	   via	   SMS	   as	   part	   of	   an	  
intervention	   programme	   increased	   vaccination	   uptake.	   [39]	   	   However,	   a	   single	   RCT	  
published	  more	  recently,	  provided	  contrasting	  results,	  concluding	  that	  an	  SMS	  intervention	  
did	  not	  significantly	   improve	  ARV	  adherence	  with	  participants	  withdrawing	  from	  the	  study	  
for	  privacy	  reasons;	  	  thus,	  the	  authors	  speculate	  that	  the	  reason	  for	  this	  ineffectivenss	  may	  
include	  the	  stigmatization	  associated	  with	  HIV	  [40].	  	  	  
Stockwell	  MS,	  2013,	  presented	  a	   literature	   review	  of	  a	  broad	   range	  of	  health	   information	  
technologies	   to	   improve	   vaccine	   communication	   and	   coverage	   and	   suggested	   that	   SMS	   is	  
effective	   in	   improving	   vaccination	   uptake	   for	   a	   number	   of	   reasons:	   (1)	   SMS	   is	   able	   to	  
penetrate	   large	   populations,	   (2)	   cost-­‐effectiveness	   given	   the	   relatively	   low	   cost,	   (3)	   less	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human	  resource	  intensive	  as	  it	  can	  be	  set	  up	  electronically,	  (4)	  reaches	  the	  specific	  patient	  
for	  which	  it	  is	  intended.	  [41]	  	  
	  
4.5	  	  	  Implications	  for	  Practice	  
The	   evidence	   presented	   in	   this	   review	   shows	   promise	   for	   the	   employment	   of	   SMS	  
interventions	  to	  promote	  the	  uptake	  of	  vaccination.	  	  However,	  the	  moderate	  quality	  of	  the	  
evidence	  implies	  that	  monitoring	  of	  the	  impact	  is	  likely	  to	  be	  needed	  and	  impact	  evaluation	  
may	  be	  warranted	  if	  SMS	  interventions	  are	  implemented	  to	  improve	  uptake	  of	  vaccination	  
services.	   Also,	   the	   specific	   contribution	   of	   educational	   messages	   combined	   with	   SMS	  
reminders	  needs	   further	  evaluation.	   	  Furthermore,	  when	  text	  messaging	   interventions	  are	  
to	   be	   introduced	   in	   resource-­‐limited	   settings,	   it	   is	   imperative	   to	   consider	   the	   potential	  
barriers	   of	   low-­‐literacy	   levels,	   language	   barriers,	   lack	   of	   access	   to	   the	   owner	   of	   a	  mobile	  
phone	  given	  that	  sharing	  of	  mobile	  phones	   is	  common	   in	  many	  places,	   restrictions	  on	  the	  
content	   of	   text	  messages,	   issues	   such	   as	   habituation	   and	   the	   ignoring	   of	  messages	  when	  
text	   messages	   are	   delivered	   too	   frequently,	   privacy	   and	   disclosure	   issues,	   poor	   mobile	  
phone	  service	  provision,	  the	  inability	  of	  mobile	  phone	  users	  to	  charge	  their	  phones	  due	  to	  
lack	   of	   electricity,	   the	   inability	   to	   buy	   pre-­‐paid	   phone	   cards	   and,	   the	   high	   incidence	   of	  
mobile	  phone	  theft	  and	  phone	  number	  changes	  in	  some	  parts	  of	  the	  world	  [14].	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4.6	  	  	  Implications	  for	  Research	  
Current	   evidence	   is	   of	   moderate	   quality.	   This	   implies	   that	   the	   likelihood	   that	   further	  
research	   will	   find	   the	   effect	   to	   be	   substantially	   different	   is	   moderate.	   	   Therefore	   more	  
research	   is	   needed	   from	   low	   and	   middle-­‐income	   countries,	   especially	   for	   non-­‐influenza	  
vaccines.	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5.	  	  Conclusion	  
The	  findings	  of	  this	  systematic	  review	  indicate	  that	  SMS	  interventions	  present	  a	  promising	  method	  
of	  promoting	  the	  uptake	  of	  vaccination.	  	  The	  results	  of	  this	  systematic	  review	  highlight	  the	  need	  for	  
further	  research	  within	  developing	  countries,	  especially	  given	  the	  rise	  of	  mobile	  phone	  usage	  in	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1.	  Stockwell	  2012	  B	  
Adolescents	  
Methods:	   Randomised	  controlled	  trial	  
Participants:	  	   Parents	  or	  guardians	  from	  a	  low-­‐income	  minority	  population	  from	  
community-­‐based	  clinics	  affiliated	  to	  the	  academic	  centre	  in	  New	  York	  City	  
were	  eligible	  to	  participate	  in	  the	  study	  if:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1)	  They	  had	  an	  11-­‐	  to	  18-­‐year-­‐old	  child	  with	  any	  visit	  (including	  sick	  visits)	  at	  
a	  study	  site	  within	  the	  previous	  12	  months.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	  The	  patient	  was	  in	  need	  of	  either	  or	  both	  MCV4	  and	  Tdap,	  or	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3)	  A	  cell	  phone	  number	  was	  recorded	  in	  the	  registration	  system.	  Parents	  of	  
patients	  who	  had	  not	  received	  the	  Tdap	  vaccine	  but	  had	  received	  another	  
tetanus-­‐containing	  vaccine	  within	  the	  previous	  2	  years	  were	  excluded	  from	  
study	  	  
Intervention:	   The	  purpose	  was	  to	  assess	  the	  effect	  of	  text	  messaging	  on	  receipt	  of	  1	  or	  
both	  of	  2	  routinely	  recommended	  adolescent	  vaccines:	  	  	  
1.	  	  MCV4	  (meningococcal)	  and	  	  
2.	  	  Tdap	  (tetanus-­‐-­‐-­‐	  diphtheria-­‐-­‐-­‐acellular	  pertussis).	  
	  
Outcomes:	   Primary	  outcome	  was	  the	  uptake	  of	  the	  Meningococcal	  (MCV4)	  and	  Tetanus,	  
diphtheria	  and	  acellular	  pertussis	  (Tdap).	  
Results:	  
At	  4	  weeks	  
Relative	  risk	   3.6484	  
95	  %	  CI	   1.6455	  to	  8.0891	  
z	  statistic	   3.186	  
P	  =	  0.0014	  
At	  12	  weeks	  
Relative	  risk	   1.9246	  
95	  %	  CI	   1.2333	  to	  3.0035	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z	  statistic	   2.884	  
P	  =	  0.0039	  
	  
At	  24	  weeks	  
Relative	  risk	   2.0147	  
95	  %	  CI	   1.3871	  to	  2.9263	  
z	  statistic	   3.678	  
P	  =	  0.0002	  
P	  =	  0.10	  
	  
Notes	  
Risk	  of	  bias	  
Bias	   Author’s	  
Judgement	  




Low	  risk	   A	  computer	  algorithm	  was	  used	  to	  automatically	  




Unclear	  risk	   The	  intervention	  patients	  were	  matched	  by	  gender	  
and	  age	  to	  randomly	  selected	  eligible	  patients	  from	  
the	  control	  sites.	  Further	  detail	  not	  provided	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	   No	  blinding,	  but	  outcome	  and	  outcome	  
measurement	  unlikely	  to	  be	  influenced	  by	  lack	  of	  
blinding	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  
Low	  risk	   No	  blinding,	  but	  outcome	  and	  outcome	  





Low	  risk	   All	  patients	  and	  outcomes	  are	  accounted	  for	  
Selective	  reporting	  
	  
Low	  risk	   Appears	  to	  be	  no	  evidence	  of	  selective	  reporting.	  
Article	  has	  been	  peer	  reviewed	  and	  published	  in	  the	  
Am	  J	  Pub	  Health	  
Other	  bias	  
	  
Low	  risk	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2.	  Stockwell	  2012	  B	  
Paediatrics	  
Methods:	   Randomised	  controlled	  trial	  
Participants:	  	   Eligible	  families	  from	  a	  low-­‐income	  minority	  population	  from	  community-­‐	  	  	  	  	  	  	  	  
based	  clinics	  affiliated	  to	  the	  academic	  centre	  in	  New	  York	  City	  had:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1)	  A	  child	  aged	  7	  to	  22	  months	  lacking	  1Hib	  dose	  needed	  to	  complete	  his	  or	  
her	  primary	  series,	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	  A	  visit	  for	  that	  child	  in	  the	  past	  12	  months	  at	  1	  of	  4	  paediatric	  clinical	  sites,	  
and	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3)	  A	  cell	  phone	  number	  recorded	  in	  the	  clinic	  registration	  system.	  
	  
Intervention:	   Conducted	  from	  May	  to	  June	  2009,	  Text4Health-­‐-­‐-­‐Peds	  was	  a	  quality	  
initiative	  to	  mobilize	  parents	  to	  attend	  special	  Hib	  immunization	  recall	  
sessions	  for	  children	  overdue	  for	  primary	  vaccination	  because	  of	  the	  national	  
shortage	  that	  occurred	  in	  response	  to	  a	  voluntary	  recall.	  




Relative	  risk	   1.8000	  
95	  %	  CI	  	   0.8818	  to	  3.6745	  
z	  statistic	   1.614	  
P	  =	  0.1064	  
	   	  





Risk	  of	  bias	  
Bias	   Author’s	  
Judgement	  




Low	  risk	   A	  computer	  algorithm	  was	  used	  to	  automatically	  




Unclear	  risk	   unclear	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	   No	  blinding,	  but	  outcome	  and	  outcome	  
measurement	  unlikely	  to	  be	  influenced	  by	  lack	  of	  
blinding	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  
Low	  risk	   No	  blinding,	  but	  outcome	  and	  outcome	  





Low	  risk	   All	  patients	  and	  outcomes	  are	  accounted	  for	  
Selective	  reporting	  
	  
Low	  risk	   Appears	  to	  be	  no	  evidence	  of	  selective	  reporting.	  
Article	  has	  been	  peer	  reviewed	  and	  published	  in	  the	  
Am	  J	  Pub	  Health	  
Other	  bias	  
	  




	   	  




3.	  Kharbanda	  2011	  
Methods:	   Site	  Based	  Intervention	  study	  (non-­‐randomised	  study)	  
Participants:	  	   Adolescent	  girls	  (9-­‐20	  years)	  from	  9	  paediatric	  clinical	  sites	  located	  in	  New	  
York	  City	  (5	  were	  hospital-­‐affiliated	  academic	  practices	  primarily	  serving	  
publicly	  insured	  youth	  and	  the	  other	  4	  were	  private	  practices)	  
Interventions:	  3	  weekly	  text	  message	  reminders	  of	  next	  vaccine	  dose	  for	  either	  HPV1	  or	  
HPV2	  
Controls:	  	   2	  control	  groups:	  
1.	  Opt-­‐out-­‐	  adolescent	  girls	  who	  had	  received	  an	  enrolment	  card	  during	  the	  
intervention	  period	  but	  did	  not	  sign	  up	  
2.	  Historical	  control	  –	  adolescent	  girls	  who	  had	  received	  the	  HPV1	  or	  HPV2	  
vaccine	  during	  the	  control	  period,	  prior	  to	  the	  start	  of	  the	  intervention.	  
Outcomes:	   Primary	  outcome:	  proportion	  of	  adolescent	  girls	  who	  received	  their	  next	  
vaccination	  on	  time	  (<92	  days	  between	  HPV1	  and	  HPV2	  &	  154	  days	  between	  
HPV2	  and	  HPV	  3).	  	  
Results:	  
Intervention	  versus	  opt-­‐out	  control	  
Relative	  risk	   1.5409	  
95	  %	  CI	  	   1.2337	  to	  1.9247	  
z	  statistic	   3.811	  
P	  =	  0.0001	  
	  
Intervention	  versus	  historical	  control	  
Relative	  risk	   1.4198	  
95	  %	  C	  I	   1.1868	  to	  1.6986	  
z	  statistic	   3.832	  
P	  =	  0.0001	  




Risk	  of	  bias	  
Bias	   Author’s	  
Judgement	  




Moderate	  risk	   Adolescents	  without	  a	  parent	  could	  self-­‐select	  to	  
participate	  in	  the	  study	  and	  those	  who	  could	  sign	  




Unclear	  risk	   unclear	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	   No	  blinding	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  








Low	  risk	   No	  evidence	  to	  support	  this	  
Other	  bias	  
	  
Low	  risk	   	  
	  
	  
	   	  




4.	  Ahlers-­‐Schmidt	  2012	  
Methods:	   Randomized	  Controlled	  Trial	  
Participants:	  	   Parents	  of	  newborns	  being	  discharged	  from	  a	  local	  hospital	  who	  intended	  to	  
seek	  child	  health	  care	  at	  the	  University-­‐sponsored	  paediatric	  resident	  and	  
faculty	  clinic	  in	  a	  Midwestern	  metropolitan	  area	  in	  Kansas.	  
Interventions:	  3	  text	  messages,	  7	  days	  prior	  to	  2,	  4,	  6	  month	  vaccinations	  to	  remind	  parents	  
that	  the	  vaccination	  was	  due	  
Outcomes:	   Receipt	  of	  immunizations	  due	  at	  2,	  4,	  6	  months	  of	  age.	  
	  
2	  month	  immunization	  received	  	  
Relative	  risk	   1.0000	  
95	  %	  CI	  0.8706	  to	  1.1487	  
z	  statistic	   0.000	  
P	  =	  1.0000	  
	  
4	  month	  immunization	  received	  	  
Relative	  risk	   0.9412	  
95	  %	  CI	  	   0.7782	  to	  1.1383	  
z	  statistic	   0.625	  
P	  =	  0.5320	  
6	  month	  immunization	  received	  	  
Relative	  risk	   0.8258	  
95	  %	  CI	  	   0.6325	  to	  1.0782	  
z	  statistic	   1.407	  
P	  =	  0.1595	  
	  




Risk	  of	  bias	  









Unclear	  risk	   Not	  detailed	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	   No	  blinding	  	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  




Moderate	  risk	   Per	  protocol	  analysis	  and	  intention	  to	  treat	  analysis	  
completed(	  2	  participants	  were	  excluded	  from	  the	  
intervention	  randomisation	  group)	  
Selective	  reporting	  
	  
Low	  risk	  	   No	  evidence	  of	  self-­‐reporting.	  Outcome	  was	  
measured	  from	  a	  clinical	  database	  
Other	  bias	  
	  
Low	  risk	   	  
	  
	   	  




Methods:	   Randomised	  controlled	  trial	  
Participants:	  	   Women	  aged	  14–50	  years	  who	  were	  pregnant	  at	  less	  than	  28	  weeks	  of	  
gestation	  recruited	  from	  the	  Pittsburgh	  Medical	  Centre,	  Pittsburgh,	  USA.	  
There	  108	  participants	  in	  the	  intervention	  group	  and	  108	  in	  the	  control	  
group.	  
Intervention:	   12	  Weekly	  text	  messages	  encouraging	  general	  pregnancy	  health	  (n	  =	  108)	  or	  
general	  pregnancy	  health	  +	  influenza	  vaccination	  (n=108).	  Duration:	  2	  
consecutive	  influenza	  seasons	  from	  2010	  –	  2012.	  
Outcomes:	   Primary	  outcome	  was	  the	  uptake	  of	  the	  influenza	  vaccination.	  
	  
Results	  
Relative	  risk	   1.0968	  
95	  %	  CI	   0.7300	  to	  1.6479	  
z	  statistic	   0.445	  
P	  =	  0.6565	  
Notes	  
Risk	  of	  bias	  









Low	  risk	   Participant’s	  names	  were	  placed	  in	  opaque	  
envelopes	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	   Health	  care	  providers	  were	  blinded	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  




Moderate	  risk	   Per	  protocol	  analysis	  done	  not	  intention-­‐to-­‐treat	  
Selective	  reporting	  
	  
Low	  risk	   Outcome	  based	  on	  clinical	  records	  
Other	  bias	  
	  
Low	  risk	   	  
	  




Methods:	   Single	  blinded	  Randomised	  controlled	  trial	  
Participants:	  	   Jan	  2010	  –	  2011,	  1998	  participants,	  permanent	  residents	  in	  Shanghai,	  China	  
aged	  between	  18–65	  years.	  Sms	  n	  =	  999.	  Control	  n	  =	  999.	  	  
Intervention:	   During	  February	  1–10,	  2010,	  one	  SMS	  message	  was	  sent	  to	  each	  participant	  
each	  morning	  for	  a	  total	  of	  ten	  different	  messages	  on	  10	  days.	  During	  the	  
subsequent	  10	  days,	  the	  same	  ten	  messages	  were	  sent	  again	  to	  each	  
participant,	  one	  daily,	  to	  reinforce	  the	  messages.	  
Outcomes:	   Self-­‐reported	  H1N1	  vaccination	  uptake.	  
	  
Results	  
Relative	  risk	   1.2928	  
95	  %	  CI	   1.0874	  to	  1.5371	  
z	  statistic	   2.909	  
P	  =	  0.0036	  
Notes	  
Risk	  of	  bias	  








Low	  risk	   unclear	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
	  
Low	  risk	  	   Single	  blinding	  reported	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
	  




Low	  risk	   All	  patients	  were	  accounted	  for	  but	  analysis	  was	  per	  
protocol	  not	  intention-­‐to-­‐treat.	  
Selective	  reporting	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Methods:	   Randomised	  controlled	  trial	  
Participants:	  	   9213	  participants	  in	  an	  urban	  low-­‐income	  paediatric	  and	  adolescent	  
population	  recruited	  from	  community-­‐based	  clinics	  in	  New	  York	  City.	  	  
Interventions:	  During	  the	  influenza	  season	  (2010-­‐2011),	  9213	  were	  randomised	  to	  SMS	  
(n=4607)	  or	  usual	  care	  (n=4606).	  Messages	  were	  sent	  5	  weekly,	  3	  were	  about	  
educational	  information	  and	  2	  about	  dates	  for	  the	  immunization	  clinics	  	  
Controls:	   n=4606	  
Outcomes:	   Primary	  outcome	  was	  receipt	  of	  an	  influenza	  vaccine	  dose	  recorded	  in	  the	  
immunization	  registry	  via	  an	  electronic	  health	  record	  by	  March	  31,	  2011.	  
Results	  	   Relative	  risk	   1.0952	  
95	  %	  CI	  	   1.0349	  to	  1.1589	  
z	  statistic	   3.150	  
P	  =	  0.0016	  
Notes	  
Risk	  of	  bias	  
Bias	   Author’s	  Judgement	   Support	  for	  judgement	  
Random	  sequence	  
generation(selection	  bias)	  
Low	  risk	   Permuted	  block	  design	  was	  utilised,	  stratified	  by	  
age	  and	  clinic	  site	  
Allocation	  
concealment(selection	  bias)	  
Unclear	  risk	   Unclear	  
Blinding	  of	  participants	  and	  
personnel(performance	  bias)	  
Unclear	  risk	   Unclear	  
Blinding	  of	  outcome	  
assessment(detection	  bias)	  
Low	  risk	   Reported	  that	  study	  analysts	  were	  blinded	  to	  
individual	  group	  assignment	  
Incomplete	  data(attrition	  
bias)	  
Low	  risk	   All	  participants	  were	  accounted	  for	  but	  per	  
protocol	  analysis	  was	  done	  and	  not	  intention	  to	  
treat	  
Selective	  reporting	   Low	  risk	   Outcomes	  were	  not	  assessed	  using	  self-­‐reporting	  
but	  online	  vaccination	  records	  
Other	  bias	   Low	  risk	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  the	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  of	  the	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  and	  should	  not	  be	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  by	  anyone	  on	  their	  behalf.	  The	  submitting	  author	  takes	  responsibility	  for	  the	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  during	  submission	  and	  peer	  review.	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  note	  that	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  levies	  an	  article-­‐processing	  charge	  on	  all	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  the	  cost	  of	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article-­‐processing	  charge	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  covered	  by	  the	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  (see	  About	  page	  for	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  that	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  submission	  if	  the	  
submitting	  author	  is	  based	  at	  the	  member	  institution.	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During	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  also	  asked	  to	  provide	  the	  contact	  details	  (including	  email	  addresses)	  of	  
potential	  peer	  reviewers	  for	  your	  manuscript.	  These	  should	  be	  experts	  in	  their	  field,	  who	  
will	  be	  able	  to	  provide	  an	  objective	  assessment	  of	  the	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  Any	  suggested	  peer	  
reviewers	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  not	  have	  published	  with	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  (PDF)	  
• TeX/LaTeX	  (use	  BioMed	  Central's	  TeX	  template)	  
• DeVice	  Independent	  format	  (DVI)	  
TeX/LaTeX	  users:	  Please	  use	  BioMed	  Central's	  TeX	  template	  and	  BibTeX	  stylefile	  if	  you	  use	  
TeX	  format.	  During	  the	  TeX	  submission	  process,	  please	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  that	  all	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  must	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  your	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  if	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  published	  articles	  are	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  manuscript	  sections	  for	  Research	  articles	  
Manuscripts	  for	  Research	  articles	  submitted	  to	  BMC	  Medicine	  should	  be	  divided	  into	  the	  
following	  sections	  (in	  this	  order):	  
• Title	  page	  
• Abstract	  
• Keywords	  
• Background	  	  
• Methods	  	  
• Results	  and	  discussion	  
• Conclusions	  
• List	  of	  abbreviations	  used	  (if	  any)	  
• Competing	  interests	  
• Authors'	  contributions	  




• Illustrations	  and	  figures	  (if	  any)	  
• Tables	  and	  captions	  
• Preparing	  additional	  files	  
The	  Accession	  Numbers	  of	  any	  nucleic	  acid	  sequences,	  protein	  sequences	  or	  atomic	  
coordinates	  cited	  in	  the	  manuscript	  should	  be	  provided,	  in	  square	  brackets	  and	  include	  the	  
corresponding	  database	  name;	  for	  example,	  [EMBL:AB026295,	  EMBL:AC137000,	  
DDBJ:AE000812,	  GenBank:U49845,	  PDB:1BFM,	  Swiss-­‐Prot:Q96KQ7,	  PIR:S66116].	  
The	  databases	  for	  which	  we	  can	  provide	  direct	  links	  are:	  EMBL	  Nucleotide	  Sequence	  
Database	  (EMBL),	  DNA	  Data	  Bank	  of	  Japan	  (DDBJ),	  GenBank	  at	  the	  NCBI	  (GenBank),	  Protein	  
Data	  Bank	  (PDB),	  Protein	  Information	  Resource	  (PIR)	  and	  the	  Swiss-­‐Prot	  Protein	  Database	  
(Swiss-­‐Prot).	  
You	  can	  download	  a	  template	  (Mac	  and	  Windows	  compatible;	  Microsoft	  Word	  98/2000)	  for	  
your	  article.	  
For	  reporting	  standards	  please	  see	  the	  information	  in	  the	  About	  section.	  	  
Title	  page	  
The	  title	  page	  should:	  
• provide	  the	  title	  of	  the	  article	  
• list	  the	  full	  names,	  institutional	  addresses	  and	  email	  addresses	  for	  all	  authors	  
• indicate	  the	  corresponding	  author	  
	   	  
Please	  note:	  
• the	  title	  should	  include	  the	  study	  design,	  for	  example	  "A	  versus	  B	  in	  the	  treatment	  of
C:	  a	  randomized	  controlled	  trial	  X	  is	  a	  risk	  factor	  for	  Y:	  a	  case	  control	  study"
• abbreviations	  within	  the	  title	  should	  be	  avoided
Abstract	  
The	  Abstract	  of	  the	  manuscript	  should	  not	  exceed	  350	  words	  and	  must	  be	  structured	  into	  
separate	  sections:	  Background,	  the	  context	  and	  purpose	  of	  the	  study;	  Methods,	  how	  the	  
study	  was	  performed	  and	  statistical	  tests	  used;	  Results,	  the	  main	  findings;	  Conclusions,	  
brief	  summary	  and	  potential	  implications.	  Please	  minimize	  the	  use	  of	  abbreviations	  and	  do	  
not	  cite	  references	  in	  the	  abstract.	  Systematic	  review	  registration,	  if	  your	  reports	  the	  
results	  of	  a	  controlled	  health	  care	  intervention,	  please	  list	  your	  registry,	  along	  with	  the	  
unique	  identifying	  number	  (e.g.	  Systematic	  review	  registration:	  PROSPERO	  
CRD0123456789).	  Please	  note	  that	  there	  should	  be	  no	  space	  between	  the	  letters	  and	  
numbers	  of	  your	  registration	  number.	  
Keywords	  
Three	  to	  ten	  keywords	  representing	  the	  main	  content	  of	  the	  article.	  
Background	  	  
The	  Background	  section	  should	  be	  written	  in	  a	  way	  that	  is	  accessible	  to	  researchers	  without	  
specialist	  knowledge	  in	  that	  area	  and	  must	  clearly	  state	  -­‐	  and,	  if	  helpful,	  illustrate	  -­‐	  the	  
background	  to	  the	  research	  and	  its	  aims.	  Reports	  of	  clinical	  research	  should,	  where	  
appropriate,	  include	  a	  summary	  of	  a	  search	  of	  the	  literature	  to	  indicate	  why	  this	  study	  was	  
necessary	  and	  what	  it	  aimed	  to	  contribute	  to	  the	  field.	  The	  section	  should	  end	  with	  a	  brief	  
statement	  of	  what	  is	  being	  reported	  in	  the	  article.	  
Methods	  
The	  methods	  section	  should	  include	  the	  design	  of	  the	  study,	  the	  setting,	  the	  type	  of	  
participants	  or	  materials	  involved,	  a	  clear	  description	  of	  all	  interventions	  and	  comparisons,	  
and	  the	  type	  of	  analysis	  used,	  including	  a	  power	  calculation	  if	  appropriate.	  Generic	  drug	  
names	  should	  generally	  be	  used.	  When	  proprietary	  brands	  are	  used	  in	  research,	  include	  the	  
brand	  names	  in	  parentheses	  in	  the	  Methods	  section.	  
For	  studies	  involving	  human	  participants	  a	  statement	  detailing	  ethical	  approval	  and	  consent	  
should	  be	  included	  in	  the	  methods	  section.	  For	  further	  details	  of	  the	  journal's	  editorial	  
policies	  and	  ethical	  guidelines	  see	  'About	  this	  journal'.	  
For	  further	  details	  of	  the	  journal's	  data-­‐release	  policy,	  see	  the	  policy	  section	  in	  'About	  this	  
journal'.	  
Results	  and	  discussion	  
The	  Results	  and	  discussion	  may	  be	  combined	  into	  a	  single	  section	  or	  presented	  separately.	  
Results	  of	  statistical	  analysis	  should	  include,	  where	  appropriate,	  relative	  and	  absolute	  risks	  
or	  risk	  reductions,	  and	  confidence	  intervals.	  The	  Results	  and	  discussion	  sections	  may	  also	  be	  
broken	  into	  subsections	  with	  short,	  informative	  headings.	  
Conclusions	  
This	  should	  state	  clearly	  the	  main	  conclusions	  of	  the	  research	  and	  give	  a	  clear	  explanation	  of	  
their	  importance	  and	  relevance.	  Summary	  illustrations	  may	  be	  included.	  
List	  of	  abbreviations	  
If	  abbreviations	  are	  used	  in	  the	  text	  they	  should	  be	  defined	  in	  the	  text	  at	  first	  use,	  and	  a	  list	  
of	  abbreviations	  can	  be	  provided,	  which	  should	  precede	  the	  competing	  interests	  and	  
authors'	  contributions.	  
Competing	  interests	  
A	  competing	  interest	  exists	  when	  your	  interpretation	  of	  data	  or	  presentation	  of	  information	  
may	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  personal	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  financial	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  required	  to	  complete	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  declaration	  of	  competing	  interests.	  All	  competing	  
interests	  that	  are	  declared	  will	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  listed	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  the	  end	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  published	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  Where	  an	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gives	  no	  competing	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  the	  listing	  will	  read	  'The	  author(s)	  declare	  that	  they	  have	  no	  
competing	  interests'.	  
When	  completing	  your	  declaration,	  please	  consider	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  following	  questions:	  
Financial	  competing	  interests	  
• In	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  past	  five	  years	  have	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  received	  reimbursements,	  fees,	  funding,	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  organization	  that	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  in	  any	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  or	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  financially	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  the	  
publication	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  this	  manuscript,	  either	  now	  or	  in	  the	  future?	  Is	  such	  an	  organization	  
financing	  this	  manuscript	  (including	  the	  article-­‐processing	  charge)?	  If	  so,	  please	  
specify.	  
• Do	  you	  hold	  any	  stocks	  or	  shares	  in	  an	  organization	  that	  may	  in	  any	  way	  gain	  or	  lose	  
financially	  from	  the	  publication	  of	  this	  manuscript,	  either	  now	  or	  in	  the	  future?	  If	  so,	  
please	  specify.	  
• Do	  you	  hold	  or	  are	  you	  currently	  applying	  for	  any	  patents	  relating	  to	  the	  content	  of	  
the	  manuscript?	  Have	  you	  received	  reimbursements,	  fees,	  funding,	  or	  salary	  from	  an	  
organization	  that	  holds	  or	  has	  applied	  for	  patents	  relating	  to	  the	  content	  of	  the	  
manuscript?	  If	  so,	  please	  specify.	  
• Do	  you	  have	  any	  other	  financial	  competing	  interests?	  If	  so,	  please	  specify.	  
Non-­‐financial	  competing	  interests	  	  
Are	  there	  any	  non-­‐financial	  competing	  interests	  (political,	  personal,	  religious,	  ideological,	  
academic,	  intellectual,	  commercial	  or	  any	  other)	  to	  declare	  in	  relation	  to	  this	  manuscript?	  If	  
so,	  please	  specify.	  
If	  you	  are	  unsure	  as	  to	  whether	  you,	  or	  one	  your	  co-­‐authors,	  has	  a	  competing	  interest	  
please	  discuss	  it	  with	  the	  editorial	  office.	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  contributions	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  order	  to	  give	  appropriate	  credit	  to	  each	  author	  of	  a	  paper,	  the	  individual	  contributions	  of	  
authors	  to	  the	  manuscript	  should	  be	  specified	  in	  this	  section.	  
According	  to	  ICMJE	  guidelines,	  An	  'author'	  is	  generally	  considered	  to	  be	  someone	  who	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Acquisition	  of	  funding,	  collection	  of	  data,	  or	  general	  supervision	  of	  the	  research	  group,	  
alone,	  does	  not	  justify	  authorship.	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  datasets	  or	  tables	  too	  wide	  for	  a	  portrait	  page	  can	  be	  uploaded	  separately	  as	  
additional	  files.	  Additional	  files	  will	  not	  be	  displayed	  in	  the	  final,	  laid-­‐out	  PDF	  of	  the	  article,	  
but	  a	  link	  will	  be	  provided	  to	  the	  files	  as	  supplied	  by	  the	  author.	  
Tabular	  data	  provided	  as	  additional	  files	  can	  be	  uploaded	  as	  an	  Excel	  spreadsheet	  (.xls	  )	  or	  
comma	  separated	  values	  (.csv).	  As	  with	  all	  files,	  please	  use	  the	  standard	  file	  extensions.	  
Preparing	  additional	  files	  
Although	  BMC	  Medicine	  does	  not	  restrict	  the	  length	  and	  quantity	  of	  data	  included	  in	  an	  
article,	  we	  encourage	  authors	  to	  provide	  datasets,	  tables,	  movies,	  or	  other	  information	  as	  
additional	  files.	  
Please	  note:	  All	  Additional	  files	  will	  be	  published	  along	  with	  the	  article.	  Do	  not	  include	  files	  
such	  as	  patient	  consent	  forms,	  certificates	  of	  language	  editing,	  or	  revised	  versions	  of	  the	  
main	  manuscript	  document	  with	  tracked	  changes.	  Such	  files	  should	  be	  sent	  by	  email	  to	  
bmcmedicineeditorial@biomedcentral.com,	  quoting	  the	  Manuscript	  ID	  number.	  
Results	  that	  would	  otherwise	  be	  indicated	  as	  "data	  not	  shown"	  can	  and	  should	  be	  included	  
as	  additional	  files.	  Since	  many	  weblinks	  and	  URLs	  rapidly	  become	  broken,	  BMC	  Medicine	  
requires	  that	  supporting	  data	  are	  included	  as	  additional	  files,	  or	  deposited	  in	  a	  recognized	  
repository.	  Please	  do	  not	  link	  to	  data	  on	  a	  personal/departmental	  website.	  The	  maximum	  
file	  size	  for	  additional	  files	  is	  20	  MB	  each,	  and	  files	  will	  be	  virus-­‐scanned	  on	  submission.	  	  
Additional	  files	  can	  be	  in	  any	  format,	  and	  will	  be	  downloadable	  from	  the	  final	  published	  
article	  as	  supplied	  by	  the	  author.	  We	  recommend	  CSV	  rather	  than	  PDF	  for	  tabular	  data.	  
Certain	  supported	  files	  formats	  are	  recognized	  and	  can	  be	  displayed	  to	  the	  user	  in	  the	  
browser.	  These	  include	  most	  movie	  formats	  (for	  users	  with	  the	  Quicktime	  plugin),	  mini-­‐
websites	  prepared	  according	  to	  our	  guidelines,	  chemical	  structure	  files	  (MOL,	  PDB),	  
geographic	  data	  files	  (KML).	  	  
If	  additional	  material	  is	  provided,	  please	  list	  the	  following	  information	  in	  a	  separate	  section	  
of	  the	  manuscript	  text:	  
• File	  name	  (e.g.	  Additional	  file	  1)	  
• File	  format	  including	  the	  correct	  file	  extension	  for	  example	  .pdf,	  .xls,	  .txt,	  .pptx	  
(including	  name	  and	  a	  URL	  of	  an	  appropriate	  viewer	  if	  format	  is	  unusual)	  
• Title	  of	  data	  
• Description	  of	  data	  
Additional	  files	  should	  be	  named	  "Additional	  file	  1"	  and	  so	  on	  and	  should	  be	  referenced	  
explicitly	  by	  file	  name	  within	  the	  body	  of	  the	  article,	  e.g.	  'An	  additional	  movie	  file	  shows	  this	  
in	  more	  detail	  [see	  Additional	  file	  1]'.	  
Additional	  file	  formats	  
Ideally,	  file	  formats	  for	  additional	  files	  should	  not	  be	  platform-­‐specific,	  and	  should	  be	  
viewable	  using	  free	  or	  widely	  available	  tools.	  The	  following	  are	  examples	  of	  suitable	  
formats.	  
• Additional	  documentation	  	  
o PDF	  (Adode	  Acrobat)	  
• Animations	  	  
o SWF	  (Shockwave	  Flash)	  
• Movies	  	  
o MP4	  (MPEG	  4)	  
o MOV	  (Quicktime)	  
• Tabular	  data	  	  
o XLS,	  XLSX	  (Excel	  Spreadsheet)	  
o CSV	  (Comma	  separated	  values)	  
As	  with	  figure	  files,	  files	  should	  be	  given	  the	  standard	  file	  extensions.	  
Mini-­‐websites	  
Small	  self-­‐contained	  websites	  can	  be	  submitted	  as	  additional	  files,	  in	  such	  a	  way	  that	  they	  
will	  be	  browsable	  from	  within	  the	  full	  text	  HTML	  version	  of	  the	  article.	  In	  order	  to	  do	  this,	  
please	  follow	  these	  instructions:	  
1. Create	  a	  folder	  containing	  a	  starting	  file	  called	  index.html	  (or	  index.htm)	  in	  the	  root.	  
2. Put	  all	  files	  necessary	  for	  viewing	  the	  mini-­‐website	  within	  the	  folder,	  or	  sub-­‐folders.	  
3. Ensure	  that	  all	  links	  are	  relative	  (ie	  "images/picture.jpg"	  rather	  than	  
"/images/picture.jpg"	  or	  "http://yourdomain.net/images/picture.jpg"	  or	  
"C:\Documents	  and	  Settings\username\My	  Documents\mini-­‐
website\images\picture.jpg")	  and	  no	  link	  is	  longer	  than	  255	  characters.	  
4. Access	  the	  index.html	  file	  and	  browse	  around	  the	  mini-­‐website,	  to	  ensure	  that	  the	  
most	  commonly	  used	  browsers	  (Internet	  Explorer	  and	  Firefox)	  are	  able	  to	  view	  all	  
parts	  of	  the	  mini-­‐website	  without	  problems,	  it	  is	  ideal	  to	  check	  this	  on	  a	  different	  
machine.	  
5. Compress	  the	  folder	  into	  a	  ZIP,	  check	  the	  file	  size	  is	  under	  20	  MB,	  ensure	  that	  
index.html	  is	  in	  the	  root	  of	  the	  ZIP,	  and	  that	  the	  file	  has	  .zip	  extension,	  then	  submit	  
as	  an	  additional	  file	  with	  your	  article.	  
Style	  and	  language	  
General	  
Currently,	  BMC	  Medicine	  can	  only	  accept	  manuscripts	  written	  in	  English.	  Spelling	  should	  be	  
US	  English	  or	  British	  English,	  but	  not	  a	  mixture.	  
There	  is	  no	  explicit	  limit	  on	  the	  length	  of	  articles	  submitted,	  but	  authors	  are	  encouraged	  to	  
be	  concise.	  There	  is	  also	  no	  restriction	  on	  the	  number	  of	  figures,	  tables	  or	  additional	  files	  
that	  can	  be	  included	  with	  each	  article	  online.	  Figures	  and	  tables	  should	  be	  numbered	  in	  the	  
order	  in	  which	  they	  are	  referred	  to	  in	  the	  text.	  Authors	  should	  include	  all	  relevant	  
supporting	  data	  with	  each	  article.	  	  
Language	  editing	  
For	  authors	  who	  wish	  to	  have	  the	  language	  in	  their	  manuscript	  edited	  by	  a	  native-­‐English	  
speaker	  with	  scientific	  expertise,	  BioMed	  Central	  recommends	  Edanz.	  BioMed	  Central	  has	  
arranged	  a	  10%	  discount	  to	  the	  fee	  charged	  to	  BioMed	  Central	  authors	  by	  Edanz.	  Use	  of	  an	  
editing	  service	  is	  neither	  a	  requirement	  nor	  a	  guarantee	  of	  acceptance	  for	  publication.	  
Please	  contact	  Edanz	  directly	  to	  make	  arrangements	  for	  editing,	  and	  for	  pricing	  and	  
payment	  details.	  
Help	  and	  advice	  on	  scientific	  writing	  
The	  abstract	  is	  one	  of	  the	  most	  important	  parts	  of	  a	  manuscript.	  For	  guidance,	  please	  visit	  
our	  page	  on	  Writing	  titles	  and	  abstracts	  for	  scientific	  articles.	  
Tim	  Albert	  has	  produced	  for	  BioMed	  Central	  a	  list	  of	  tips	  for	  writing	  a	  scientific	  manuscript.	  
American	  Scientist	  also	  provides	  a	  list	  of	  resources	  for	  science	  writing.	  For	  more	  detailed	  
guidance	  on	  preparing	  a	  manuscript	  and	  writing	  in	  English,	  please	  visit	  the	  BioMed	  Central	  
author	  academy.	  
Abbreviations	  
Abbreviations	  should	  be	  used	  as	  sparingly	  as	  possible.	  They	  should	  be	  defined	  when	  first	  
used	  and	  a	  list	  of	  abbreviations	  can	  be	  provided	  following	  the	  main	  manuscript	  text.	  
Typography	  
• Please	  use	  double	  line	  spacing.	  
• Type	  the	  text	  unjustified,	  without	  hyphenating	  words	  at	  line	  breaks.	  
• Use	  hard	  returns	  only	  to	  end	  headings	  and	  paragraphs,	  not	  to	  rearrange	  lines.	  
• Capitalize	  only	  the	  first	  word,	  and	  proper	  nouns,	  in	  the	  title.	  
• All	  pages	  should	  be	  numbered.	  
• Use	  the	  BMC	  Medicine	  reference	  format.	  
• Footnotes	  are	  not	  allowed,	  but	  endnotes	  are	  permitted.	  
• Please	  do	  not	  format	  the	  text	  in	  multiple	  columns.	  
• Greek	  and	  other	  special	  characters	  may	  be	  included.	  If	  you	  are	  unable	  to	  reproduce	  a	  
particular	  special	  character,	  please	  type	  out	  the	  name	  of	  the	  symbol	  in	  full.	  Please	  
ensure	  that	  all	  special	  characters	  used	  are	  embedded	  in	  the	  text,	  otherwise	  they	  
will	  be	  lost	  during	  conversion	  to	  PDF.	  
Units	  
SI	  units	  should	  be	  used	  throughout	  (liter	  and	  molar	  are	  permitted,	  however).	  
	  
